documents incorporated reference part incorporated scheringplough corporation proxy part iii statement annual meeting shareholders april table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters item selected financial data item managements discussion analysis financial condition results operation item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules reports form k signatures global note global note letter agreement employment agreement amendment supplement employment agreement supplement employment agreement operations management team incentive plan cash longterm incentive plan longterm performance share unit incentive plan transformational performance shares program distribution agreement computation ratio earnings fixed charges code ethics subsidiaries consent deloitte touche llp power attorney certification certification certification certificationtable contents part item business terms scheringplough company used herein refer scheringplough corporation subsidiaries except otherwise indicated context scheringplough corporation incorporated trademarks indicated capital letters property licensed promoted distributed scheringplough corporation subsidiaries related companies subsidiaries scheringplough engaged discovery development manufacturing marketing pharmaceutical products worldwide discovery development efforts target field human health occasionally applications field animal health result efforts company views animal health applications means maximize return investments discovery development company operates primarily prescription pharmaceutical marketplace however appropriate company sought may future seek regulatory approval switch prescription products overthecounter otc status means extending products life cycle way otc marketplace yet another means maximizing return investments discovery development november company announced five formulations claritin brand nondrowsy allergy products approved original prescription strengths fda otc medicines treatment allergies company launched otc claritin united states december also december competing otc loratadine product launched united states third quarter company began face additional privatelabel competition otc claritin line nonsedating antihistamines initial day period exclusivity expired first otc generic competitor company continues market clarinex desloratadine mg tablets treatment allergic rhinitis combines indication seasonal allergic rhinitis indication perennial allergic rhinitis well treatment chronic idiopathic urticaria hives unknown cause ability company capture maintain market share clarinex otc claritin us market depend number factors including additional entrants market allergy treatments clinical differentiation clarinex allergy treatments perception extent differentiation marketplace pricing differentials among otc claritin clarinex allergy treatments generic otc loratadine erosion rate otc claritin clarinex sales upon entry additional generic otc loratadine products whether one branded secondgeneration antihistamines switched prescription otc status clarinex experiencing intense competition prescription us allergy market prescription allergy market shrinking since otc switch claritin december company implementing new marketing efforts address market share performance clarinex table contents switch claritin otc status introduction competing otc loratadine resulted rapid sharp material decline claritin sales united states companys results operations us sales prescription claritin products million percent companys consolidated global sales billion percent sales clarinex united states abroad also materially adversely affected presence generic otc loratadine otc claritin light factors described management believes companys december introduction otc claritin well introduction competing otc loratadine product december additional entrants generic otc loratadine products market rapid sharp material adverse effect companys results operations likely continue indeterminate period time company merck co inc merck agreements jointly develop market zetia ezetimibe oncedaily monotherapy coadministration zetia statins ezetimibe oncedaily fixedcombination tablet simvastatin zocor mercks cholesterolmodifying medicine agreements also involve development marketing oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january scheringploughmerck pharmaceuticals reported results phase iii clinical trials fixedcombination tablet containing claritin singulair demonstrate sufficient added benefits treatment seasonal allergic rhinitis october merckscheringplough pharmaceuticals announced fda approved zetia ezetimibe mg use either together statins treatment elevated cholesterol levels march company announced ezetimibe ezetrol marketed europe successfully completed european union eu mutual recognition procedure mrp completion mrp process eu member states well iceland norway grant national marketing authorization unified labeling ezetrol ezetrol launched many international markets agreements generally provide equal sharing development costs copromotion approved products company united states countries world except japan japan agreement exists general copromotion provides company provide equal physician marketing efforts company bear cost sales force marketing products general agreement provides venture operate virtual mode maximum degree possible relying respective infrastructures two companies however companies agreed share certain costs costs limited portion costs manufacturing cost specialty sales force certain specially identified promotion costs noted company incurs substantial costs selling costs reflected equity income cholesterol joint venture borne entirely company agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either merck company table contents additional prescription products sold company include asmanex celestamine foradil nasonex polaramine proventil allergyrespiratory caelyx cedax ethyol eulexin garamycin intron pegintron rebetol ribavirin remicade temodar anti infective anticancer diprolene diprosone elocon lotrisone quadriderm valisone dermatologicals integrilin kdur nitro dur cardiovasculars celestone diprospan subutex temgesic pharmaceuticals pegintron rebetol combination therapy hepatitis c contributed substantially sales fourth quarter competing pegylated interferonbased combination product including brand ribavirin received regulatory approval major markets including united states overall market share intron franchise declined sharply reflecting new market competition management believes ability pegintron rebetol combination therapy maintain market share continue adversely affected new competition hepatitis c marketplace animal health products include cepravin nuflor antimicrobials banamine zubrin nonsteroidal antiinflammatories ralgro growth promotant implant otomax otic product broad range vaccines many species parasiticides sutures bandages nutritional products foot care otc sun care products include clear away wart remover dr scholls foot care products lotrimin tinactin antifungals ointment afrin nasal decongestant chlortrimeton antihistamine claritin allergy coricidin drixoral cold decongestant products correctol laxative bain de soleil coppertone solarcaine sun care products recent developments response decline sales earnings company initiated number actions including new management team appointed implemented many changes described following sections quarterly dividend reduced cents cents per common share program entitled value enhancement initiative vei commenced vei tool designed enable company save spend wisely key costcutting initiatives implemented include eliminating employee bonuses companys standard plans table contents eliminating payout companys profit sharing plan eliminating routine merit increases throughout exceptions local contracts practices prevent action customer contact employees employees dedicated fulfillment companys fda consent decree obligations businesscritical employees targeting overall reduction payroll related expenses least percent excluding payroll expense associated customer contact employees employees dedicated fulfilling companys fda consent decree obligations first step toward achieving target voluntary early retirement program verp united states approximately employees elected retire program installing global procurement programs exercising tight controls new hires cutting back travel costs reducing meeting expenses table contents net sales major product therapeutic category dollars millions years ended december percent change vs antiinfective anticancer caelyx intron franchise remicade temodar antiinfective anticancer allergy respiratory clarinex claritin rx nasonex proventil allergy respiratory cardiovasculars integrilin cardiovasculars dermatologicals pharmaceuticals worldwide pharmaceuticals otc nm otc claritin nm otc foot care sun care animal health consolidated net sales nm meaningful intron franchise consists intron pegintron rebetol sales clarinex launched international markets included claritin rx sales table contents company three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent companys current management reporting structure established second quarter prior period information presented herein restated comparable basis prescription pharmaceuticals segment discovers develops manufactures markets human ethical pharmaceutical products consumer health care segment develops manufactures markets otc foot care sun care products animal health segment discovers develops manufactures markets animal health products net sales segment dollars millions year ended december prescription pharmaceuticals consumer health care animal health consolidated net sales profit segment dollars millions year ended december prescription pharmaceuticals consumer health care animal health corporate consolidated lossprofit tax corporate includes charges million related voluntary early retirement program see special charges footnote item financial statements supplementary data additional information estimated charges relate reportable segments follows prescription pharmaceuticals million consumer health care million animal health million corporate million corporate also includes provisions increase litigation reserves asset impairment charges interest income expense foreign exchange gains losses headquarters expenses miscellaneous items accounting policies used segment reporting described summary significant accounting policies table contents company subsidiaries countries outside united states sales outside united states comprised percent million consolidated net sales percent million percent million single foreign country except france japan italy accounted percent consolidated net sales past three years france accounted percent million percent million percent million consolidated net sales respectively japan accounted percent million percent million percent million consolidated net sales respectively italy accounted percent million percent million percent million consolidated net sales respectively net sales geographic area dollars millions united states europe canada latin america pacific area asia consolidated net sales net sales presented geographic area companys customers located percent million percent million percent million respectively consolidated net sales made mckesson corporation major pharmaceutical health care products distributor also percent million percent million percent million respectively consolidated net sales made amerisourcebergen corporation major pharmaceutical health care products distributor longlived assets geographic location dollars millions united states ireland singapore puerto rico total longlived assets shown geographic location primarily property table contents sales products comprising percent companys us international sales year ended december follows dollars millions us international intron franchise clarinex otc claritin remicade company disaggregate assets segment basis internal management reporting therefore information presented prescription drugs introduced made known physicians pharmacists hospitals managed care organizations buying groups trained professional sales representatives sold hospitals certain managed care organizations wholesale distributors retail pharmacists prescription products also introduced made known journal advertising direct mail advertising distributing samples physicians television radio internet print advertising media animal health products promoted veterinarians distributors animal producers foot care otc sun care products sold wholesale retail drug food chain mass merchandiser outlets promoted directly consumer television radio internet print advertising media pharmaceutical industry highly competitive includes large companies substantial resources research product development advertising promotion field selling support numerous domestic international competitors industry principal competitive techniques used company products include research development new improved products high product quality varied dosage forms strengths switching prescription products nonprescription status united states many companys products subject increasingly competitive pricing managed care groups institutions federal state government entities agencies buying groups seek price discounts rebates governmental pressures toward dispensing generic products may significantly reduce sales certain products become longer protected patents data exclusivity arrangements fda companys subsidiaries licensed rights number patents patent applications united states abroad patents patent applications relating companys significant products including without limitation clarinex claritin family products intron peg intron rebetol nasonex zetia material importance company compound patent loratadine expired june table contents us market exclusivity claritin expired december patent covering compound desloratadine formulations thereof methods treatment desloratadine relates claritin set expire april six months us market exclusivity would attach end desloratadine patent relates claritin would expire october sixmonth period exclusivity granted company conducted pediatric clinical trials request fda addition generic forms ribavirin expected enter us market assuming fdas approval generic ribavirin patents subject litigation described item legal proceedings worldwide companys products sold trademarks trademarks considered aggregate material importance business protected registration common law united states markets products sold raw materials essential company available adequate quantities number potential suppliers energy expected available company sufficient quantities meet operating requirements seasonal patterns pronounced effect consolidated operations company foreign operations foreign activities carried primarily whollyowned subsidiaries wherever market potential adequate circumstances permit addition company represented markets licensees distribution arrangements approximately employees outside united states foreign operations subject certain risks inherent conducting business overseas risks include possible nationalization expropriation importation limitations pricing restrictions restrictive governmental actions economic destabilization also fluctuations foreign currency exchange rates impact companys consolidated financial results additional information foreign operations see item managements discussion analysis operations financial condition segment information described research development companys research activities primarily aimed discovering developing new enhanced prescription products medical commercial significance company sponsored research development expenditures million million million respectively research expenditures represented approximately percent consolidated net sales percent consolidated net sales approximately percent consolidated net sales addition companys share research development costs relating cholesterol joint venture merck table contents million included equity income cholesterol joint venture statements consolidated operations companys research activities concentrated therapeutic areas allergic inflammatory disorders infectious diseases oncology cardiovascular diseases central nervous system disorders company also substantial efforts directed toward biotechnology gene therapy immunology research activities include expenditures internal research efforts research collaborations various partners several pharmaceutical compounds varying stages development predicted compounds become available commercial sale government regulation pharmaceutical companies subject extensive regulation number national state local agencies particular importance fda jurisdiction companys businesses administers requirements covering testing approval safety effectiveness manufacturing labeling marketing companys products fda also regulates conversion pharmaceuticals prescription otc status extent fda requirements andor reviews affects amount resources necessary develop new products bring market united states ongoing basis fda regulates facilities procedures used manufacture pharmaceutical products united states sale united states products made facilities manufactured accordance good manufacturing practices gmps established fda fda periodically inspects companys facilities procedures evaluate compliance may company announced reached agreement fda consent decree resolve issues involving companys compliance current good manufacturing practices cgmp certain manufacturing facilities new jersey puerto rico us district court district new jersey approved entered consent decree may terms consent decree company agreed pay total million us government two equal installments million first installment paid may second installment paid may previously reported company accrued million provision consent decree fourth quarter consent decree requires company complete number actions event certain actions agreed upon consent decree satisfactorily completed time fda may assess payments deadline missed consent decree required company develop submit fdas concurrence comprehensive cgmp work plans companys manufacturing facilities new jersey puerto rico covered decree company received fda concurrence proposed cgmp work plans may table contents cgmp work plans contain number significant steps whose timely satisfactory completion subject payments thousand per business day deadline missed payments may exceed million million years payments subject overall cap million connection discussions fda regarding companys cgmp work plans pursuant terms decree company fda entered letter agreement dated april letter agreement company fda agreed extend six months time period company may incur payments described respect certain significant steps whose proposed due dates december letter agreement increase yearly overall caps payments described addition decree requires company complete programs revalidation finished drug products bulk active pharmaceutical ingredients manufactured covered manufacturing facilities company required consent decree complete revalidation programs bulk active pharmaceutical ingredients september finished drugs december general timely satisfactory completion revalidations subject payments thousand per business day deadline missed subject caps described however product scheduled revalidation certified validated last date validation schedule fda may assess payment percent net domestic sales uncertified product validation certified general product scheduled revalidation consent decree certified within six months scheduled date company must cease production product certification obtained completion significant steps work plans completion revalidation programs subject thirdparty expert certification must accepted fda consent decree provides company believes may able meet deadline company right upon showing good cause request extensions deadlines connection cgmp work plans revalidation programs however guarantee fda grant requests although company believes made significant progress meeting obligations consent decree possible company may fail complete significant step revalidation prescribed deadline third party expert may certify completion significant step revalidation fda may disagree experts certification significant step revalidation case possible fda may assess payments described company would expense payments assessed decree incurred failure comply governmental regulations result delays release products delays approvals new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions table contents companys activities outside united states also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing companys products regulatory requirements vary country country whether fda approval approval european medicines evaluation agency obtained product approval product comparable regulatory authorities countries outside united states european union case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required united states approval one country assure product approved another country international markets company operates environment governmentmandated costcontainment programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods cost control recent years various legislative proposals offered congress many state legislatures would effect major changes affected health care systems one change could material company addition outpatient prescription drug benefit medicare states passed legislation federal state legislative administrative proposals possible could include price patient reimbursement constraints medicines mandated discounts supplemental rebates expansion existing governmental programs new patient populations restrictions access certain products similar issues also arisen many countries outside united states possible predict outcome initiatives effect operations cash flows reasonably estimated company predict net effect medicare prescription drug benefit markets sales program go effect many companys leading drugs already covered medicare part b eg temodar integrilin intron others relatively small portion sales medicare population eg clarinex hepatitis c franchise company could experience expanded utilization zetia new drugs companys rd pipeline greater consequence company may legislations impact pricing rebates discounts company also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission ftc department justice department health human services united states company therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies table contents environment date compliance federal state local environmental protection laws materially adverse effect company company made continue make necessary expenditures environmental protection worldwide capital expenditures included approximately million environmental control purposes anticipated continued compliance environmental regulations significantly affect companys financial statements competitive position additional information environmental matters see item legal proceedings employees approximately people employed company december available information company makes annual report quarterly reports form q current reports form k amendments reports filed sec available free charge web site soon reasonably practicable materials electronically filed sec companys address world wide web scheringploughcom since company began practice third quarter report available companys web site within hours filing reports filed company sec may read copied secs public reference room fifth street nw washington dc information operation public reference room may obtained calling sec sec sec also maintains internet site wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec item properties companys corporate headquarters located kenilworth new jersey principal manufacturing facilities located kenilworth new jersey miami florida omaha nebraska cleveland tennessee puerto rico argentina belgium canada france germany ireland italy japan mexico singapore spain companys principal research facilities located kenilworth union new jersey palo alto san diego california elkhorn nebraska may company announced reached agreement fda enter consent decree resolve issues involving companys compliance cgmp certain manufacturing facilities new jersey puerto rico refer government regulation section within item form k additional information regarding consent decree table contents properties owned company properties generally well maintained insured generally good operating condition companys manufacturing facilities capacities considered appropriate meet companys needs table contents item legal proceedings background company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law company alleged potentially responsible party prp company estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps company records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated company also involved various claims legal proceedings nature considered normal business including product liability cases company adjusts accrued liabilities reflect current best estimate probable loss exposure best estimate determinable company accrues minimum amount within probable range liability recorded liabilities matters december related expenses incurred months ended december material expected insurance recoveries considered determining costs environmentalrelated liabilities management believes except matters discussed remainder section remote time material liability excess amounts accrued incurred respect matters discussed remainder section except noted practicable estimate range reasonably possible loss reserve included financial statements resolution matters discussed remainder section individually aggregate could material adverse effect companys results operations financial condition management reviews status matters discussed remainder section ongoing basis time time may settle otherwise resolve terms conditions management believes best interests company company aware settlements matters types set forth remainder section particular investigations frequently involve fines andor penalties material financial condition results operations entity entering settlement assurances company prevail matters settlements reached acceptable terms including scope release provided amounts exceed amounts reserved even acceptable settlement reached assurance investigations litigations commenced raising similar type issues potentially exposing company additional material liabilities company predict timing resolution matters outcomes table contents environmental residents vicinity publicly owned wastewater treatment plant barceloneta puerto rico filed two lawsuits plant owner operator numerous companies discharge plant including subsidiary company damages injunctive relief relating odors allegedly coming plant connecting sewers one lawsuits class action claiming damages million trial date set cases matter submitted mediation november received general notice potential liability epa addressed arnoscholls adhesive tapes inc former subsidiary company relating lake culmet cluster site chicago illinois several hundred potentially responsible parties site scheringplough responded information request new jersey department environmental protection relating contamination lower passaic river basin scheringplough denied connection contamination late september department directed prps contaminated sites assess restore natural resource damage lower passaic river basin department name scheringplough prp however department sent scheringplough letter received september stating company may legally responsible damages natural resources state department adopted regulations covering liability calculated making difficult accurately predict ultimate extent companys exposure patent matters claritin patents february geneva pharmaceuticals inc geneva submitted abbreviated new drug application anda us fda seeking market generic claritin tablets expiration companys desloratadine compound patent company believes protects claritin geneva alleged desloratadine compound patent invalid patent material companys business march company filed suit federal court seeking ruling genevas anda submission constitutes infringement companys desloratadine compound patent challenge patent without merit addition geneva following companies made similar anda submissions generic claritin tablets zenith goldline pharmaceuticals mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc ranbaxy genpharm incorporated l perrigo company perrigo following companies made similar anda submissions generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax made similar anda submissions generic claritind hour claritind hour formulations ranbaxy made similar anda submission generic claritind hour formulation esi lederle inc lederle subsidiary wyeth made similar anda submission generic claritin reditab formulation following companies submitted paper new drug applications paper ndas section b federal food drug cosmetic act seeking market generic otc form claritin prior expiration companys desloratadine compound patent whitehall table contents robins healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablets perrigo otc tablets case company filed suit federal court seeking ruling applicable anda paper nda submission proposed marketing generic prescription otc product constitutes infringement companys desloratadine compound patent challenge patent without merit august federal district court new jersey ruled motions summary judgment finding certain claims desloratadine compound patent anticipated prior patent thus valid august district courts decision sustained appellate court october appellate court denied companys petition rehearing rulings actions defendants infringement desloratadine compound patent manufacturers loratadine proceed company also asserted impaxs andrxs andas generic claritind hour formulations infringe companys patent covering claritind hour formulation october company settled litigation impax andrx licensed patent rebetol patents august geneva pharmaceuticals technology corp geneva pharmaceuticals three rivers pharmaceuticals llc three rivers january teva submitted separate andas fda seeking market generic forms mg rebetol ribavirin capsules united states expiration companys patents covering ribavirin formulations geneva pharmaceuticals three rivers teva asserted infringe companys rebetol patents andor patents invalid rebetol patents material companys business september october march company filed suits federal court seeking rulings anda submissions geneva pharmaceuticals three rivers teva respectively constitute infringement companys patents challenges companys patents without merit company entered separate licensing agreements three rivers geneva pharmaceuticals teva settled patent litigation company three rivers teva geneva pharmaceuticals granted three rivers geneva pharmaceuticals teva nonexclusive nonsublicensable license companys us ribavirin patents agreements subject dismissal three rivers geneva pharmaceuticals tevas reported patent litigation ribapharm inc subsidiary valeant pharmaceuticals international ribapharm litigation dismissed upon defendants motion summary judgment july ribapharm appealed summary judgment decision ribapharm also petitioned fda deny approval three rivers geneva pharmaceuticals teva products fda acted ribapharm petition date report prime pac prrs patent january jury found companys prime pac prrs porcine respiratory reproductive syndrome vaccine infringed patent owned boehringer ingelheim vetmedica inc injunction issued august barring sales companys vaccine companys posttrial motions either reversal jurys verdict new trial denied september company appealed verdict affirmed appellate court february litigation damages phase case ongoing trial determine damages scheduled may table contents investigations pennsylvania investigation october company received subpoena us attorneys office eastern district pennsylvania pursuant health insurance portability accountability act concerning companys contracts pharmacy benefit managers pbms managed care organizations provide disease management services connection marketing pharmaceutical products appears subpoena one number addressed industry participants part inquiry among things pharmaceutical marketing practices governments inquiry focused among things whether companys disease management marketing programs arrangements comply federal health care laws whether value disease management programs marketing programs arrangements included calculation rebates government company cooperating investigation march us attorneys office began issuing grand jury subpoenas grand jury investigation appears focused one transactions managed care organizations government believes company offered provided deeply discounted pharmaceutical products known nominally priced products generally excluded medicaid rebate calculations free discounted disease management services marketing programs arrangements delivered value order place retain one companys major pharmaceutical products managed care organizations formulary grand jury appears investigating among things whether transactions described conduct relating thereto violated federal antikickback statutes ii whether value items services described included companys calculation medicaid rebates outcome investigations could include commencement civil andor criminal proceedings involving substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company predict whether investigations affect marketing practices sales third quarter company increased litigation reserves related investigation investigations described us attorneys office district massachusetts million increase reserves reflects maturing discussions offices particularly eastern district pennsylvania adjustment companys estimate minimum liability relating investigations compliance us generally accepted accounting principles gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made fourth quarter company increased litigation reserves million matters company predict timing resolution matters company notes total reserves reflect estimate final settlement adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company awp investigations company responding investigations department health human services department justice committee energy commerce us house representatives certain states certain industry company practices regarding average wholesale price awp investigations include department justice table contents review merits federal action filed private entity behalf united states us district court southern district florida well investigation us attorneys office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp march company received subpoena massachusetts attorney generals office seeking documents concerning use awp pricing andor marketing practices company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies massachusetts investigation us attorneys office district massachusetts also investigating whether companys sales product manufactured private label arrangement managed care organization included companys medicaid best price calculations early november company served two additional grand jury subpoenas us attorney district massachusetts among information subpoenas seek broad range information concerning companys sales marketing clinical trial practices programs respect intron rebetron temodar companys sales marketing contacts managed care organizations doctors companys offering provision grants honorariums items services value managed care organizations physician groups doctors educational institutions company understands investigation focused whether certain sales marketing clinical trial practices conduct related thereto certain instances relate use one abovementioned products indications fda approval obtained socalled offlabel uses violation federal laws regulations respect offlabel promotional activities investigation also appears focus whether drug samples clinical trial grants items services value given providers incentivize prescribe one abovementioned products including offlabel uses violation federal health care antikickback laws company implemented certain changes sales marketing clinical trial practices continuing review practices ensure compliance relevant laws regulations company cooperating investigations future sales intron rebetron temodar may adversely affected company time predict ultimate impact sales outcome investigations could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs third quarter company increased litigation reserves related investigations us attorneys office district massachusetts described paragraph paragraph immediately preceding investigation described us attorneys office eastern district pennsylvania million increased litigation reserves reflect adjustment companys estimate minimum liability relating investigations compliance gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made fourth quarter company increased litigation reserves million matters company notes total reserves reflect estimate final settlement table contents adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company company predict timing resolution matters outcomes reported k filed may scheringplough disclosed connection abovedescribed investigations us attorneys office district massachusetts sales marketing clinical trial practices among matters may schering corporation wholly owned significant operating subsidiary scheringplough received letter boston target letter office advising schering corporation including subsidiaries divisions target federal criminal investigation respect four areas providing remuneration drug samples clinical trial grants items services value managed care organizations physicians others induce purchase schering pharmaceutical products payment made federal health care programs sale misbranded unapproved drugs company understands mean drugs promoted indications approval us fda obtained socalled offlabel uses submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program failing include prices products repackaging arrangement managed care customer well prices free nominally priced goods provided customer induce purchase schering products document destruction obstruction justice relating governments investigation target defined department justice guidelines person prosecutor grand jury substantial evidence linking commission crime judgment prosecutor putative defendant us attorneys manual section consumer products matter us department justice antitrust division investigating whether companys consumer products division entered agreement another company lower commission rate consumer products broker february antitrust division served grand jury subpoena company seeking documents first time company cooperating investigation nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product table contents sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates securities class action litigation february company stated press release fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed us district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed complaints consolidated one action us district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described second sentence paragraph purporting represent class shareholders purchased shares company stock may february companys motion dismiss consolidated amended complaint denied may october court certified shareholder class discovery ongoing addition lawsuits described immediately preceding paragraph two lawsuits filed us district court district new jersey two lawsuits filed new jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described companys february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorneys offices eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick pharmaceuticals warrick companys generics subsidiary described herein lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending us district court district new jersey consolidated one action early stages january company received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three table contents directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside counsel advise issued report findings investigation independent directors board late october report determined shareholder demand refused finding liability part officers directors november full board adopted recommendation evaluation committee august prescription access litigation project pal bostonbased group formed litigate drug companies issued press release stating pal members filed lawsuit new jersey state court company december company served amended complaint case suit pal purports class action alleges among things companys directtoconsumer advertising falsely depicts benefits claritin violation new jersey consumer fraud act february company filed motion dismiss case may court dismissed complaint entirety failure state claim plaintiffs appeal denied new jersey state court plaintiffs requested new jersey supreme court hear case request denied ending litigation company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price laxatives phenylpropanolaminecontaining coughcold remedies ppa products purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased would paid less products known certain defects medical risks attendant use litigation claims relating companys ppa products courts national class action suit several state class action suits denied certification dismissed suits similar application dismiss new jersey remaining statewide class action suit involving company pending approximately individual lawsuits relating laxative products ppa products recalled albuterolvancerilvancenase inhalers also pending company seeking recovery personal injuries death number lawsuits punitive damages claimed march company served putative class action complaint filed us district court new jersey alleging company richard jay kogan resigned chairman board november retired chief executive officer president director company april companys employee savings plan plan administrator breached fiduciary obligations certain participants plan allegations primarily relate disclosures companys good manufacturing practices issues discussed earlier securities class action litigation section relation companys disclosures consent decree fda related matters disclosures meetings investors week september communications discussed sec inquiry related litigation may table contents company served second putative class action complaint filed court allegations nearly identical complaint filed march october consolidated amended complaint filed names additional defendants following directors eugene mcgrath donald miller carl mundy patricia russo kathryn turner two former directors james wood regina herzlinger corporate officers consolidated amended complaint also contains allegations associated boston target letter described investigations section footnote company filed motion dismiss complaint august lawsuit filed new jersey superior court chancery division union county served company nominal defendant companys outside directors alleging breach fiduciary duty directors relating companys receipt boston target letter described investigations section footnote action temporarily stayed pending adjudication separate related action framed shareholder request access companys books records seeking documents information relating massachusetts investigation antitrust ftc matters company defendant numerous antitrust actions commenced starting state federal courts independent retail pharmacies chain retail pharmacies consumers plaintiffs allege price discrimination andor conspiracy company defendants restrain trade jointly refusing sell prescription drugs discounted prices plaintiffs company february agreed settle federal class action behalf approximately twothirds retail pharmacies united states total million paid full us district court illinois approved settlement federal class action seventh circuit court appeals dismissed appeals settlement subject review april certain plaintiffs federal class action commenced another purported class action us district court illinois company defendants settled previous federal class action complaint alleges defendants conspired implement settlement commitments following settlement discussed district court denied plaintiffs motion preliminary injunction hearing company either settled dismissed motion state court retailer consumer actions settlement amounts material company federal court illinois remanded conspiracy portion cases retailers opted class action back district courts filed cases consolidated federal district court brooklyn new york federal court illinois jurisdiction robinson patman portion cases trial conspiracy claims set begin october plaintiffs antitrust actions generally seek treble damages unspecified amount injunction allegedly unlawful conduct table contents april ftc started administrative proceeding company upshersmith inc upshersmith lederle complaint alleges anti competitive effects settlement patent lawsuits company lederle company upshersmith lawsuits settled related generic versions kdur companys longacting potassium chloride product subject andas filed lederle upshersmith june administrative law judge overseeing case issued decision patent litigation settlements complied law respects dismissed claims company appeal decision full commission filed ftc staff december full commission issued opinion reversed decision administrative law judge found violation antitrust laws ruling instead companys settlements fact violate laws ftcs decision involve monetary penalty company appealed decision federal court appeals kdur potassium chloride supplement used cardiac patients following commencement ftc administrative proceeding alleged class action suits filed behalf direct indirect purchasers kdur company upshersmith lederle federal state courts suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action motion dismiss actions pending pricing matters third quarter warrick pharmaceuticals warrick companys generics subsidiary sued state texas june company subsidiary schering corporation added defendants lawsuit alleges warrick supplied state false reports wholesale prices caused state pay medicaid claims prescriptions warricks albuterol sulfate solution inhaler higherthanjustified level state seeks damages approximately million warrick including treble damages penalties trial date april set outcome litigation could result imposition fines penalties injunctive remedies case goes trial assurances damages sought state exceed amount set forth states petition december pal filed class action suit federal court massachusetts company september consolidated complaint filed court result coordination multidistrict litigation panel federal court awp cases throughout country consolidated complaint alleges company warrick conspired providers defraud consumers reporting fraudulently high awps prescription medications reimbursed medicare thirdparty payers complaint seeks declaratory judgment unspecified damages including treble damages included pal litigation described prior paragraph lawsuits allege company warrick reported inflated awps prescription pharmaceuticals thereby caused state federal entities thirdparty payers make excess reimbursements providers actions also allege company warrick failed report accurate prices medicaid rebate program thereby underpaid rebates states actions began october brought state attorneys general table contents private plaintiffs nonprofit organizations employee benefit funds allege violations federal state law including fraud antitrust racketeer influenced corrupt organizations act rico claims addition warrick company defendants number lawsuits state courts actions generally brought states andor political subdivisions seek unspecified damages including treble punitive damages sec inquiries related litigation sec investigating compliance polish subsidiaries certain pharmaceutical companies us foreign corrupt practices act pursuant order dated november company voluntarily produced documents related polish subsidiary subsidiaries countries company continues cooperate secs requests company also cooperating inquiries police katowice poland asking related information september sec company announced settlement sec enforcement proceeding company richard jay kogan former chairman chief executive officer regarding meetings held investors week september communications without admitting denying allegations company agreed commit future violations regulation fd related securities laws paid civil penalty million mr kogan paid civil penalty thousand federal putative class actions filed company mr kogan regarding meetings held investors week september communications consolidated pursuant consolidation amended complaint dated march filed alleging violations sections b securities exchange act relating alleged disclosures made meetings mentioned paragraph company filed motion dismiss class actions may plaintiffs sought leave court thereafter filed second amended complaint october company moved dismiss second amended complaint september lawsuit filed new jersey superior court union county richard jay kogan companys outside directors alleging breach fiduciary duty fraud deceit negligent misrepresentation relating alleged disclosures made meetings mentioned company removed case federal court motion remand state court pending matters company subject pharmacovigilance reporting requirements many countries jurisdictions including united states european union eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea serious deficiencies reporting processes identified company taking table contents urgent actions rectify deficiencies quickly possible company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products april company received notice false claims act complaint brought individual purporting act behalf us government approximately pharmaceutical companies us district court northern district texas complaint alleges pharmaceutical companies including company defrauded united states made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices company defendants filed motion dismiss action july tax matters october irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax income tax sought irs auditors relating recharacterization approximately million plus interest depending upon court company chooses litigate case may required pay tax possibly interest prior litigation company estimates interest approximately million company prevail litigation amounts paid prior litigation would returned company plus accrued interest company could also choose litigate case court would require payment tax interest prior litigation management believes probable matter litigated management also believes tax reserves sufficient absorb loss resulting unfavorable outcome litigation item submission matters vote security holders applicable table contents executive officers registrant following information regarding executive officers included herein accordance part iii item corporate officers also listed officers elected serve one year successors shall duly elected name current position business experience age robert j bertolini present position executive vice president chief partner pricewaterhousecoopers financial officer c ron cheeley present position senior vice president group vice president global compensation global human resources benefits pharmacia corporation joseph c connors present position executive vice president general counsel carrie cox present position executive vice president president executive vice president president global global pharmaceuticals prescription business pharmacia corporation senior vice president head global business management pharmacia upjohn douglas j gingerella present position vice president corporate staff vice president corporate audits audits fred hassan present position chairman chief executive officer chairman board chief executive officer president pharmacia corporation chief executive officer pharmacia corporation chief executive officer pharmacia upjohn table contents name current position business experience age thomas h kelly present position vice president controller joseph j larosa present position staff vice president secretary staff vice president commercial law associate general counsel senior legal director legal director e kevin moore present position vice president treasurer daniel nichols present position senior vice president taxes cecil b pickett phd present position vice president president schering executive vice president discovery research plough research institute scheringplough research institute brent saunders present position senior vice president global partner pricewaterhousecoopers chief compliance business practices risk officer coventry health care officers defined rule af securities exchange act table contents part ii item market registrants common equity related stockholder matters common share dividends share price data approximate number holders record set forth item financial statements supplementary data item selected financial data dollars millions except per share figures operating results net sales lossincome income taxes net lossincome diluted lossearnings per common share basic lossearnings per common share investments research development capital expenditures financial condition property net total assets longterm debt shareholders equity net book value per common share financial statistics net lossincome percent sales return average shareholders equity effective tax rate data cash dividends per common share cash dividends common shares depreciation amortization number employees average shares outstanding diluted earnings per common share millions average shares outstanding basic earnings per common share millions common shares outstanding yearend millions table contents include special charges respectively see special charges footnote item financial statements supplementary data additional information effective tax rate percent excluding nontax deductible provision increase litigation reserves table contents item managements discussion analysis financial condition results operation executive summary company scheringplough worldwide pharmaceutical company committed discovering developing manufacturing marketing new therapies treatments enhance human health companys primary business strategy continually discover license human pharmaceutical products patent protected extended period time products patent expires generic competition occurs resulting substantial decline products average selling price scheringplough also leading consumer product brands overthecounter otc foot care sun care markets global animal health business government regulatory agencies throughout world regulate companys discovery development manufacturing marketing efforts food drug administration united states fda pivotal regulator companys business united states pricing companys pharmaceutical products subject competitive pressure managed care organizations seek price discounts also united states company required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs international markets company operates environment government mandated costcontainment programs company ships pharmaceutical products wholesalers distributors markets products health care professionals managed care organizations lesser extent patients key performance indicators kpis company percentage market shares products market shares companys major products discussed sections follow current state company past three years company experienced confluence negative events summarized follows since company working fda resolve issues involving companys compliance current good manufacturing practices cgmp certain manufacturing sites new jersey puerto rico company reached formal agreement fda consent decree terms consent decree company agreed make payments totaling million revalidate manufacturing processes sites manufacturing sites remained opened throughout period however consent table contents decree placed significant additional controls production release products sites including review thirdparty certification production variances products review thirdparty certification batch production records thirdparty certifications cgmp improvement projects resulted higher costs well reduced output facilities addition company found necessary discontinue certain older products impact consent decree discussed detail sections follow certain companys sales marketing practices investigation us attorneys offices pennsylvania massachusetts investigations pose significant risks company caused company significantly increase litigation reserves matters discussed detail sections follow december company switched formulations claritin united states prescription otc status switch followed loss marketing exclusivity product average unit selling price otc product much lower price prescription market loss marketing exclusivity company faces additional competition comparable brands generics otc marketplace claritin united states companys leading product terms sales even terms profit result company experienced rapid sharp material decline earnings cash flow beginning company expect earnings recover loss sales claritin time company introduces new products recovery may take several years companys leading franchise combination pegylated interferon pegintron ribavirin rebetol treat hepatitis c late competitor entered hepatitis c marketplace versions pegylated interferon ribavirin prior introduction competing products company held leading position hepatitis c market introduction competitor companys market shares fallen significantly decline sales exacerbated overall earnings cash flow decline addition generic forms rebetol may approved time important us market occur companys market shares sales would decline table contents matters resulted following cash flow declined significantly particularly united states majority research conducted dividends paid also payments arising investigations conducted us attorneys offices could reduce cash flow united states addition companys credit ratings reduced impact lower credit ratings companys overall liquidity discussed detail sections follow companys manufacturing sites operate well optimum levels due sales declines reduction output related consent decree time overall costs operating manufacturing sites increased due consent decree activities impact facts reduction profit margins time major investments manufacturing capacity impaired however company continues review carrying value assets indications impairment future events decisions may lead asset impairment losses accelerated depreciation due shortened asset lives response company initiated following actions new management team appointed implemented many changes described following sections quarterly dividend reduced cents cents per common share program entitled value enhancement initiative vei commenced vei tool designed enable company save spend wisely key costcutting initiatives implemented include eliminating employee bonuses companys standard plans eliminating payout companys profit sharing plan eliminating routine merit increases throughout exceptions local contracts practices prevent action customer contact employees employees dedicated fulfillment companys fda consent decree obligations businesscritical employees targeting overall reduction payroll related expenses least percent excluding payroll expense associated customer contact employees employees dedicated fulfilling companys fda consent decree obligations first step toward achieving target voluntary early retirement program verp united states approximately employees elected retire program installing global procurement programs exercising tight controls new hires cutting back travel costs reducing meeting expenses table contents positive side company entering cholesterolreduction market launch zetia ezetimibe us marketing application ezetimibesimvastatin combination submitted filing september cholesterolreduction market single largest pharmaceutical market world management believes products potential enabling company move beyond loss claritin build long term financial strength addition company believes several potentially valuable pharmaceutical compounds earlier stage research pipeline company also aggressively pursuing licensing opportunities researchbased pharmaceutical companies outlook yearoveryear comparisons negatively impacted number factors including following company experienced downward slopes sales market share several key profitgenerating products throughout much company making significant investments sales marketing support aimed stabilizing market shares key profitgenerating products company expects generic competition rebetol us market begin contraction worldwide hepatitis c market began may continue absence losec revenues europe due end agreement astrazeneca third quarter losec revenues million ability company rebuild financial strength highly dependent upon success cholesterol joint venture merck co inc merck joint venture highly successful company may able rebuild financial strength turn around operating performance beginning joint venture highly successful company must rely success earlystage pipeline drugs licensing opportunities significant change corporate strategy combination reader note significant uncertainty inherent factors could enable company rebuild financial strength net sales consolidated net sales totaled billion decrease billion percent compared period consolidated net sales reflected volume decline percent favorable foreign exchange rate impact percent unfavorable price impact percent net sales united states decreased percent versus net sales internationally advanced percent international sales included favorable foreign exchange rate impact percent table contents consolidated net sales billion increased million percent versus reflecting price increase impact percent favorable foreign exchange rate impact percent sales volume unchanged versus net sales major therapeutic category years ended december follows dollars millions increase decrease antiinfective anticancer allergy respiratory cardiovasculars dermatologicals pharmaceuticals global pharmaceuticals otc nm foot care sun care consumer health care animal health consolidated net sales nm meaningful percentage certain prior year amounts reclassified conform current year presentation net sales global antiinfective anticancer products decreased percent compared sales intron franchise used primarily treatment hepatitis c decreased percent billion due market share declines changes us trade inventory levels lower sales japan market share intron franchise declining reflecting entrance competitors new products hepatitis c market also previously reported company anticipates potential generic competition united states rebetol us sales rebetol million intron franchise includes anticancerantiviral agent intron injection monotherapy combination rebetol capsules treating hepatitis c peg intron powder injection longeracting form intron monotherapy combination rebetol treating hepatitis c net sales antiinfective anticancer therapeutic category benefited international sales remicade treatment rheumatoid arthritis crohns disease ankylosing spondylitis net sales remicade million percent million primarily europe due increased patient utilization global sales temodar capsules treating certain types brain tumors increased percent million due increased market penetration international sales caelyx longcirculating pegylated liposomal formulation doxorubicin hydrochloride increased percent million due increased table contents patient utilization coupled ongoing launch new indication treatment metastatic breast cancer patients increased cardiac risk net sales global antiinfective anticancer products rose percent compared led october market introduction pegintron combination rebetol hepatitis c united states continued rollout combination therapy european markets december launch rebetol combination intron japan sales antiinfective anticancer category also benefited higher international sales remicade global sales temodar reflecting increased market penetration global net sales allergy respiratory products decreased percent percent category sales negatively impacted rapid decline sales prescription claritin resulting loss market exclusivity united states along conversion prescription otc status december global sales prescription claritin million compared billion billion us sales prescription claritin recognized million versus sales billion billion global net sales clarinex treatment seasonal outdoor allergies yearround indoor allergies million increase percent reflecting continued conversion patients prescription claritin clarinex coupled launch clarinex several international markets factors tempered contraction us prescription antihistamine market following launch otc claritin well changes us trade inventory levels clarinex continues experience intense competition us allergy market global sales clarinex million clarinex launched united states january net sales nasonex nasal spray oncedaily corticosteroid nasal spray allergies decreased percent million due changes us trade inventory levels market share declines united states nasonex experiencing intense competition us allergy market international sales nasonex grew percent million due market share gains net sales nasonex essentially flat versus due market share declines united states tempered market share gains international markets global net sales cardiovascular products increased percent sales integrilin injection glycoprotein platelet aggregation inhibitor treatment patients acute coronary syndromes increased percent million due increased patient utilization united states tempered decline us trade inventory levels global net sales cardiovascular products decreased percent due lower sales kdur sustainedrelease potassium chloride supplement subject generic competition partially offsetting decline higher sales integrilin due increased patient utilization increased market penetration net sales consumer health care products include otc foot care sun care products increased million percent increased million otc product net sales increased million million due launch otc table contents claritin december sales otc claritin million million third quarter company began face additional privatelabel competition otc claritin initial day period exclusivity expired first otc generic competitor comparison versus negatively impacted manufacturing issues otc products net sales foot care products decreased million percent due nonrecurrence launch lotrimin ultra topical antifungal foot care sales decreased percent due increasing competition tempered launch lotrimin ultra net sales sun care products decreased million percent primarily due unfavorable weather conditions united states sun care sales decreased percent due lower sales bain de soleil products global net sales animal health products increased percent million sales favorably impacted foreign exchange percent offset continued manufacturing supply issues described additional factors influencing operations global net sales animal health products decreased percent due challenging global market conditions coupled manufacturing issues table contents summary costs expenses equity income dollars millions increase decrease cost sales net sales selling general administrative net sales research development net sales income expense net nm net sales special charges nm net sales equity income cholesterol joint venture nm net sales nm meaningful percentage certain prior year amounts reclassified conform current year presentation cost sales percentage net sales increased primarily due change product sales mix resulting loss us sales prescription claritin increase also result higher unit manufacturing costs including effect lower production volumes coupled increased spending companys cgmp compliance efforts cost sales percentage net sales increased primarily due shift sales towards products royalties paid higher costs associated manufacturing issues selling general administrative expenses decreased percent billion versus billion decrease mostly due lower marketing expenses global pharmaceutical business including zero payout profit sharing routine bonuses addition field force incentives also declined decreases tempered higher promotion otc claritin foreign exchange ratio net sales percent higher ratio percent primarily due lower overall sales reported selling general administrative expenses increased percent ratio net sales increased percent percent due increased spending support continued rollout new recently introduced products international markets research development spending increased percent billion representing percent net sales research development expenses increased percent table contents billion represented percent net sales changes spending years reflect timing companys funding internal research efforts research collaborations various partners discover develop steady flow innovative products change also reflects presentation research development costs related cholesterol collaboration merck equity method accounting discussed income expense net included higher net interest expense income expense net included million income related sale companys us marketing rights suboxone subutex sublingual tablets treatment opioid dependence see income expense net footnote additional information special charges components special charges follows dollars millions employee termination costs asset impairment losses litigation charges consent decree charge table contents employee termination costs august company announced global workforce reduction initiative first phase initiative verp united states program eligible employees united states december elect early retirement receive enhanced retirement benefit approximately employees elected retire program approximately employees retired near yearend approximately employees staggered retirement dates future total cost program estimated million comprised increased pension costs million increased postretirement health care costs million vacation payments million costs related accelerated vesting stock grants million employees staggered retirement dates future amounts recognized special charge employees remaining service periods delayed expense recognition follows guidance statement financial accounting standards sfas accounting costs associated exit disposal activities amounts recognized program million amounts expected recognized million million respectively expected cash expenditures associated program million million respectively also included employee termination costs table million employee severance costs december company announced targeting overall reduction payroll related expenses least percent excluding payroll expenses associated customercontact employees employees dedicated fulfilling companys fda consent decree obligation target includes savings realized verp company expects incur additional employee termination costs associated achieving goal reducing payroll related expenses savings expected realized actions approximate million annually company expects reinvest significant portion savings expanding sales forces maximize zetia ezetimibesimvastatin opportunities support nasonex remicade intron franchise asset impairment losses asset impairment losses recognized accordance sfas goodwill intangible assets sfas accounting impairment disposal longlived assets asset impairment losses related following company ceased production certain products produced one manufacturing sites operating fda consent decree company also announced closure manufacturing site england manufacturing site england substantially ceased sales affected products table contents material asset impairment loss million based discounted cash flows recognized related facilities equipment two sites company ceased marketing licensed cancer therapy drug sold countries outside united states sales product declined material introduction competing products resulted decline market share companys drug point management concluded longer practical continue participate marketplace asset impairment loss million based discounted cash flows recognized related intangible asset one companys sun care brands competes highend segment overall sun care market two large cosmetics companies entered market segment sales companys brand declined company acquired brand portion purchase price allocated trade name based upon fair value time company performs periodic reviews values assigned intangible assets connection reviews impairment loss million related trade name recognized based discounted cash flows reflects change market conditions since brand acquired sales sun care brand material litigation charges litigation reserves increased million million respectively primarily result investigations companys sales marketing practices see legal environmental regulatory matters footnote additional information consent decree charge provision million recognized payments federal government consent decree see consent decree footnote additional information table contents summary selected special charges following summarizes activity accounts related employee termination costs asset impairment losses amounts millions employee asset termination impairment costs losses special charges impairment writeoff credit retirement benefit plan liability cash disbursement special charges accrual balance dec balance december employee termination costs represents value stock grants million distributed yearend severance accrued vacation payments paid million equity income cholesterol joint venture effective company presenting collaboration merck jointly develop market zetia ezetimibesimvastatin combination following equity method accounting method company records share operating profits less share research development costs equity income cholesterol joint venture included line full year companys share operating profits million million milestone receipt less share research development costs million noted company incurs substantial costs selling costs reflected equity income cholesterol joint venture borne entirely company zetia launched united states several international markets november several additional market launches occurred date global sales zetia million prior venture research development phase companys share research development expense million million respectively reported research development statements consolidated operations net lossincome net lossincome loss million versus income billion billion respectively net lossincome includes special charges million described net income includes million pretax provision increase litigation reserves includes million pretax provision consent decree payments provisions included special charges effective tax rate full year effective tax rate percent excluding million nontax deductible provision increase litigation reserves effective tax rate percent company reduced effective tax rate due decrease profits primarily united states additional information see income taxes footnote notes consolidated financial statements impact potential early termination swaps discussed liquidity financial resources may result higher effective tax rate beyond lossearnings per common share diluted lossearnings per common share decreased loss increased percent earnings weakening us dollar foreign currencies increased growth earnings per common share diluted earnings per share reflect favorable exchange impacts respectively company advises trend earnings viewed without aforementioned special charges impact yeartoyear changes foreign exchange rates table contents liquidity financial resources background following background information may useful reader understanding current state companys liquidity financial resources december approximately percent cash cash equivalents shortterm investments shown accompanying balance sheet held wholly owned foreignbased subsidiaries time substantially debt shown accompanying balance sheet owed parent company wholly owned usbased subsidiaries years prior geographic disparity location funds location debt pivotal issue company however material decline earnings following loss marketing exclusivity claritin united states geographic disparity taken importance cash cash equivalents plus shortterm investments exceeded total debt december billion however using funds held foreign based subsidiaries cash needs usbased subsidiaries may result us income tax payments amount us income tax payments would depend upon number factors including amount funds used whether us operations generating taxable profits losses us operations generated tax losses primarily due decline claritin sales continued investment research development entire amount us tax losses used recoup taxes paid previous years carryback benefit management expects us operations generate tax losses however portion losses expected used recoup taxes paid previous years current law carryback benefit exhausted amount expected loss excess used recoup taxes paid previous years becomes available reduce taxable income future carryforward benefit us operations generate losses used recoup taxes paid previous years company choice either use carryforward benefits future years utilize losses absorb taxable distributions us cash assets held foreignbased subsidiaries absorbing us operating losses manner allows portion assets held foreignbased subsidiaries become available use us operations without make us income tax payments discussed company expects finance portion cash needs possibly beyond accessing funds held foreign based subsidiaries funds company expects access represent foreign earnings generated beyond company expect incur additional us income taxes accessing funds taxable distributions absorbed expected us operating table contents losses described company may make additional taxable distributions funds held foreignbased subsidiaries us operations company triggered credit rating downgrade provisions certain financing arrangements company may incur additional us income taxes additional distributions foreignbased subsidiaries may exceed us operating losses discussion cash flow cash provided operating activities totaled million million million cash provided operating activities declined due lower sales claritin lower sales products within intron franchise higher manufacturing costs portion cash flow impact lower sales mitigated collection accounts receivable followed decline sales cash provided operating activities also includes second payment million relating fda consent decree previous filings company reported possibly beyond cash provided operating activities would sufficient fund working capital capital expenditures dividends items remained thencurrent levels response decline sales earnings well likelihood declines company announced august reduction quarterly dividend cents cents per common share action saves approximately million per quarter beginning fourth quarter day company also announced accelerated intensified costcutting actions including global workforce reduction effort shown statements consolidated cash flows cash needs working capital capital expenditures dividends exceeded cash operations excess cash needs cash generation occurred entirely within us operations deficit approximately million foreign operations generated cash excess cash needs company borrowed additional funds united states finance us operations continuing accumulate cash foreignbased subsidiaries management expects foreign operations generate cash us operations cash needs however excluding potential payments arising litigation investigations discussed us deficit expected decline dividend payments approximately million less company expects receive tax refund excess million carryback benefit described approximately million cash available us december pay commercial paper balances fund us operations discussion take consideration payments may arise matters described legal environmental regulatory matters footnote included financial statements report particular company accrued material amounts respect investigations conducted us attorneys offices pennsylvania table contents massachusetts respect dispute irs time management estimate ultimate amounts timing potential payments certainty payments would increase cash needs us operations may necessitate additional financing repatriation funds held foreignbased subsidiaries combination two matters may also affect companys credit ratings ability access commercial paper companys current cash management strategy capital structure remain unchanged beyond management expects cash held foreign based subsidiaries debt owed usbased subsidiaries increase management process evaluating whether present strategies structure appropriate light increasing debt levels well changing portfolio companys products management believes company possesses sufficient financial resources meet financial needs company excess billion cash cash equivalents shortterm investments albeit held foreignbased subsidiaries well sizable lines credit commercial banks described management believes company continuing access capital markets borrowings credit facilities november company issued billion aggregate principal amount percent senior unsecured notes due billion aggregate principal amount percent senior unsecured notes due proceeds offering billion used general corporate purposes including repay commercial paper outstanding united states upon issuance notes rated moodys investors service moodys creditwatch negative implications standard poors sp interest rates payable notes subject adjustment rating assigned notes either moodys sp downgraded respectively interest rate payable series notes increase see financial instruments commitments footnote included financial statements report additional information company three revolving credit facilities totaling billion recently negotiated facility september billion day credit facility three major financial institutions drawn united states facility matures september facilities syndicate financial institutions provide million drawn united states may repayment due may second multi currency facility million drawn united states internationally maturity date may december funds drawn facilities december shortterm borrowings totaled million approximately percent outstanding commercial paper commercial paper ratings discussed significantly affected companys ability issue roll outstanding commercial paper borrowings time however ability commercial paper issuers table contents company one shortterm credit ratings p moodys sp andor f fitch ratings fitch issue roll outstanding commercial paper times less companies higher shortterm credit ratings addition total amount commercial paper capacity available issuers typically less higher rated companies company maintains sizable lines credit commercial banks well cash shortterm investments held foreignbased subsidiaries serve alternative sources liquidity support commercial paper program credit ratings december sp lowered companys corporate credit longterm debt ratings said outlook ratings negative noting weakening companys intron franchise expected declines earnings cash flows change companys shortterm corporate credit commercial paper rating lowered july january sp placed companys corporate credit rating shortterm credit rating senior unsecured debt rating creditwatch negative implications february sp downgraded companys senior unsecured debt ratings time sp also lowered companys shortterm corporate credit commercial paper rating sp removed company creditwatch however outlook remains negative october moodys lowered companys corporate credit rating lowered commercial paper rating p p following rating action moodys removed company watchlist revised rating outlook stable negative moodys also stated credit rating assumed modest outflows settle outstanding litigation acquisitions large payment associated litigation proceedings acquisition activity could place pressure rating andor outlook november fitch downgraded companys senior unsecured bank loan ratings commercial paper rating f f companys rating outlook remained negative announcing downgrade fitch noted sales decline companys leading product franchise intron franchise greater anticipated concerned total company growth reliant performance two key growth drivers zetia remicade near term table contents financial arrangements containing credit rating downgrade triggers company two separate arrangements enable manage cash flows us subsidiaries foreignbased subsidiaries arrangements employ interest rate swaps arrangements similar credit rating downgrade triggers allow counterparty call early termination credit rating downgrade triggers require company maintain longterm debt rating least moodys sp sps moodys current credit ratings specified minimum result counterparty interest rate swaps elect early termination following specified period described one arrangements utilizes two longterm interest rate swap contracts one foreignbased subsidiary bank us subsidiary bank two contracts equal offsetting terms covered master netting arrangement contract involving foreignbased subsidiary permits subsidiary prepay portion future obligation bank contract involving us subsidiary permits bank prepay portion future obligation us subsidiary interest paid prepaid balances parties market rates prepayments totaling billion made contracts december prepaid amounts netted preparation consolidated balance sheet accordance financial accounting standards board fasb interpretation offsetting amounts related certain contracts arrangement provides event company fails maintain required minimum credit ratings counterparty may terminate transaction designating early termination date earlier months following date notice terminate however notice given early termination consequences discussed would occur end threeyear period early termination requires repayment prepaid amounts repayment must occur original tax jurisdiction prepaid amounts made accordingly early termination would require companys us subsidiary repay billion bank bank repay billion companys foreignbased subsidiary financial impact early termination depends manner extent company decides finance us repayment obligation company could finance entire obligation obtaining short longterm financing united states case cash debt would increase equal amounts consolidated balance sheet however companys ability finance obligation swaps depend companys credit ratings business operations well market conditions time financing contemplated alternatively company could repatriate united states funds received foreignbased subsidiary repatriating funds could us income tax consequences depending primarily profitability us operations tax would accrued future earnings may result company reporting higher effective tax rate currently us operations generating tax losses however future tax table contents losses may insufficient absorb potential tax company repatriate funds received foreignbased subsidiary stated termination transaction occur earlier months following date company receives termination notice counterparty accordingly early termination imminent due fact well alternative courses action available company event early termination potential early termination impact current liquidity financial resources second arrangement utilizes longterm interest rate swap contracts one entered notional principal million second entered notional principal million terms contracts enable company sell right receive payments retaining obligation make payments us parent company sold rights receive payments contracts foreignbased subsidiary return approximately million fair value intercompany transaction eliminated preparation consolidated financial statements internal revenue service asserted transactions sale loan additional us income taxes due company expects litigate matter described legal environmental regulatory matters footnote financial statements contracts allow counterparty effectively terminate transaction company fails maintain required minimum credit ratings within days restore least one required minimum credit ratings companys credit rating fell required minimum credit rating february unlikely company restore least one credit ratings allotted time early termination contracts due credit rating downgrade would likely result us parent company reacquiring right receive payments foreignbased subsidiary terminating transaction counterparty net basis reacquisition rights receive payments swap contracts would occur either us parent company buying back rights fair market value foreignbased subsidiary dividend rights back us parent company buying back rights would necessitate funding united states company currently estimates would approximately million case cash debt would increase equal amounts consolidated balance sheet alternatively foreignbased subsidiary dividend rights back us parent company could result additional us income taxes presently us operations company generating tax losses losses expected exceed value intercompany dividend necessary reacquire rights result event early termination management alternative reacquiring rights terminating transaction counterparty without materially impacting liquidity financial resources accordingly management view early termination arrangement material event impacting current liquidity financial resources table contents contractual obligations payments due period companys known contractual obligations december follows dollars millions payments due period less total year years years years longterm debt obligations operating lease obligations purchase obligations advertising contracts research contracts capital expenditure commitments purchase orders recorded longterm liabilities total longterm debt obligations include million aggregate principal amount percent senior unsecured notes due million aggregate principal amount percent senior unsecured notes due see financial instruments commitments footnote notes consolidated financial statements additional information research contracts include potential milestone payments made since payments contingent occurrence certain events table also excludes research contracts cancelable company without penalty open purchase orders consist cancelable noncancelable inventory expense items caption includes obligations based undiscounted amounts estimated payments certain companys pension plans hold qualified assets estimated payments companys deferred compensation plans environmental matters company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund environmental expenditures based information currently available anticipated material impact company additional information see legal environmental regulatory matters footnote notes consolidated financial statements table contents additional factors influencing operations united states many companys pharmaceutical products subject increasingly competitive pricing managed care groups institutions government agencies groups seek price discounts international markets company operates environment governmentmandated cost containment programs us market company pharmaceutical manufacturers required provide statutorily defined rebates various government agencies order participate medicaid veterans health care program governmentfunded programs several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs enacted acrosstheboard price cuts methods control costs since company unable predict final form timing future domestic international governmental health care initiatives including passage laws permitting importation pharmaceuticals united states effect operations cash flows reasonably estimated similarly effect operations cash flows decisions government entities managed care groups groups concerning formularies pharmaceutical reimbursement policies reasonably estimated company predict net effect medicare prescription drug benefit markets sales program go effect many companys leading drugs already covered medicare part b eg temodar integrilin intron others relatively small portion sales medicare population eg clarinex hepatitis c franchise company could experience expanded utilization zetia new drugs companys rd pipeline greater consequence company may legislations impact pricing rebates discounts significant portion net sales made major pharmaceutical health care products distributors major retail chains united states consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors market pharmaceutical products competitive companys operations may affected technological advances competitors industry consolidation patents granted competitors new products competitors generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products effect operations competitive factors patent disputes predicted noted legal environmental regulatory matters footnote included financial statements report company sued drug manufacturers marketing seeking market certain forms generic loratadine prior expiration companys compound patent desloratadine case company filed suit federal court seeking ruling applicable abbreviated new drug application anda paper new drug application submission proposed marketing generic prescription otc product table contents constitute infringement companys patents challenge patents without merit compound patent loratadine expired june us market exclusivity claritin expired december patent covering compound desloratadine formulations thereof methods treatment desloratadine relates claritin set expire april six months us market exclusivity would attach end desloratadine patent relates claritin would expire october sixmonth period exclusivity granted company conducted pediatric clinical trials request fda august federal district court new jersey ruled motions summary judgment finding certain desloratadine compound patent claims company believes protect claritin anticipated prior patent thus valid august district courts decision sustained appellate court october appellate court denied companys petition rehearing rulings actions defendants infringement desloratadine compound patent manufacturers loratadine proceed company also asserted andas filed two manufacturers generic versions claritind hour infringe companys patent covering claritind hour company settled litigation impax andrx october licensed patent november company announced five formulations claritin brand nondrowsy allergy products approved original prescription strengths fda otc medicines treatment allergies company also informed fda new drug applications ndas claritin formulations well indications allergies hives transferred fdas pulmonary division office drug evaluation ii division overthecounter drug products office drug evaluation v company launched otc claritin united states december also december competing otc loratadine product launched united states third quarter company began face additional privatelabel competition otc claritin line nonsedating antihistamines initial day period exclusivity expired first otc generic competitor company continues market clarinex desloratadine mg tablets treatment allergic rhinitis combines indication seasonal allergic rhinitis indication perennial allergic rhinitis well treatment chronic idiopathic urticaria hives unknown cause ability company capture maintain market share clarinex otc claritin us market depend number factors including additional entrants market allergy treatments clinical differentiation clarinex allergy treatments perception extent differentiation marketplace pricing differentials among otc claritin clarinex allergy treatments generic otc loratadine erosion rate otc claritin clarinex sales upon entry additional generic otc loratadine products whether one branded secondgeneration antihistamines switched prescription otc status clarinex experiencing intense competition prescription us allergy market prescription allergy market shrinking since otc switch claritin table contents december company implementing new marketing efforts address market share performance clarinex switch claritin otc status introduction competing otc loratadine resulted rapid sharp material decline claritin sales united states companys results operations us sales prescription claritin products million percent companys consolidated global sales billion percent sales clarinex united states abroad also materially adversely affected presence generic otc loratadine otc claritin light factors described management believes companys december introduction otc claritin well introduction competing otc loratadine product december additional entrants generic otc loratadine products market rapid sharp material adverse effect companys results operations likely continue indeterminate period time disclosed filings us securities exchange commission sec noted legal environmental regulatory matters footnote included financial statements report three drug manufacturers submitted andas fda seeking market generic forms rebetol ribavirin capsules united states expiration companys patents covering ribavirin formulations company sued manufacturers federal court infringement company entered separate licensing agreements three rivers pharmaceuticals llc three rivers geneva pharmaceuticals inc geneva teva pharmaceuticals usa inc teva settled patent litigation company three rivers geneva teva granted three companies nonexclusive nonsublicensable license companys us ribavirin patents settlements affect three rivers genevas tevas reported patent litigation ribapharm inc subsidiary valeant pharmaceuticals international ribapharm relating ribavirin patents litigation dismissed upon defendants motion summary judgment july ribapharm appealed summary judgment decision ribapharm also petitioned fda deny approval three rivers geneva teva products fda acted ribapharm petition generic forms ribavirin expected enter us market assuming fdas approval generic ribavirin rebetol patents material companys business us sales rebetol million pegintron rebetol combination therapy hepatitis c contributed substantially sales fourth quarter competing pegylated interferonbased combination product including brand ribavirin received regulatory approval major markets including united states overall market share intron franchise declined sharply reflecting new market competition management believes ability pegintron rebetol combination therapy maintain market share continue adversely affected new competition hepatitis c marketplace october merckscheringplough pharmaceuticals announced fda approved zetia ezetimibe mg use either together statins treatment elevated cholesterol levels march company announced ezetimibe ezetrol table contents marketed europe successfully completed european union eu mutual recognition procedure mrp completion mrp process eu member states well iceland norway grant national marketing authorization unified labeling ezetrol ezetrol launched many international markets merckscheringplough partnership also pursuing development marketing oncedaily tablet combining ezetimibe simvastatin zocor mercks cholesterolmodifying medicine uncertainties inherent government regulatory approval processes including among things delays approval new products formulations indications may also affect companys operations effect regulatory approval processes operations predicted company subject jurisdiction various national state local regulatory agencies therefore subject potential administrative actions particular importance fda united states jurisdiction companys businesses administers requirements covering testing safety effectiveness approval manufacturing labeling marketing companys products time time agencies including fda may require company address various manufacturing advertising labeling regulatory issues noted relating companys current manufacturing issues failure comply governmental regulations result delays release products seizure recall products suspension revocation authority necessary production sale products discontinuance products fines civil criminal sanctions result could material adverse effect companys financial position results operations additional information regarding government regulation may affect future results provided part item business companys annual report fiscal year ended december additional information cautionary factors may affect future results provided caption cautionary factors may affect future results cautionary statements private securities litigation reform act managements discussion analysis operations financial condition noted consent decree footnote included financial statements report may company announced reached agreement fda consent decree resolve issues involving companys compliance current good manufacturing practices certain manufacturing facilities new jersey puerto rico us district court district new jersey approved entered consent decree may terms consent decree company agreed pay total million us government two equal installments million first installment paid may second installment paid second quarter previously reported company accrued million provision consent decree fourth quarter consent decree requires company complete number actions event certain actions agreed upon consent decree satisfactorily completed time fda may assess payments deadline missed consent decree required company develop table contents submit fdas concurrence comprehensive cgmp work plans companys manufacturing facilities new jersey puerto rico covered decree company received fda concurrence proposed cgmp work plans may cgmp work plans contain number significant steps whose timely satisfactory completion subject payments per business day deadline missed payments may exceed million million years payments subject overall cap million connection discussions fda regarding companys cgmp work plans pursuant terms decree company fda entered letter agreement dated april letter agreement company fda agreed extend six months time period company may incur payments described respect certain significant steps whose proposed due dates december letter agreement increase yearly overall caps payments described addition decree requires company complete programs revalidation finished drug products bulk active pharmaceutical ingredients manufactured covered manufacturing facilities company required consent decree complete revalidation programs bulk active pharmaceutical ingredients september finished drugs december general timely satisfactory completion revalidations subject payments per business day deadline missed subject caps described however product scheduled revalidation certified validated last date validation schedule fda may assess payment percent net domestic sales uncertified product validation certified general product scheduled revalidation consent decree certified within six months scheduled date company must cease production product certification obtained completion significant steps work plans completion revalidation programs subject thirdparty expert certification must accepted fda consent decree provides company believes may able meet deadline company right upon showing good cause request extensions deadlines connection cgmp work plans revalidation programs however guarantee fda grant requests although company believes made significant progress meeting obligations consent decree possible company may fail complete significant step revalidation prescribed deadline third party expert may certify completion significant step revalidation fda may disagree experts certification significant step revalidation case possible fda may assess payments described company would expense payments assessed decree incurred table contents addition failure meet terms consent decree could result delays approval new products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions april company received notice false claims act complaint brought individual purporting act behalf us government approximately pharmaceutical companies us district court northern district texas complaint alleges pharmaceutical companies including company defrauded united states made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices company defendants filed motion dismiss action july company subject pharmacovigilance reporting requirements many countries jurisdictions including united states european union eu eu member states requirements differ jurisdiction jurisdiction include requirements reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea serious deficiencies reporting processes identified company taking urgent actions rectify deficiencies quickly possible company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products described specifically legal environmental regulatory matters footnote included financial statements report reader report directed pricing sales marketing programs arrangements related business practices company participants health care industry increasing scrutiny federal state regulatory investigative prosecutorial administrative entities entities include department justice us attorneys offices office inspector general department health human services fda federal trade commission ftc various state attorneys general offices many health care laws certain governmental entities operate including federal state antikickback statutes statutory common law false claims laws construed broadly courts permit government entities exercise significant discretion event governmental entities believes wrongdoing occurred one could institute civil criminal proceedings instituted resolved unfavorably could subject company substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company also predict whether investigations affect marketing practices table contents sales result could material adverse effect company financial condition results operations critical accounting policies following accounting policies considered significant changes certain judgments assumptions inherent policies could affect companys financial statements accrual rebates sales pharmaceuticals united states provision income taxes undistributed foreign earnings intercompany pricing matters impairment intangible assets accounting legal regulatory matters pharmaceutical products sold direct purchasers eg wholesalers retailers certain health maintenance organizations company invoices entities products shipped addition company commercial rebate discount arrangements certain indirect purchasers market participants eg managed care organizations indemnify beneficiaries health plans pharmaceutical costs pharmacy benefit managers based upon purchase utilization company products company also governmental rebate obligations certain federal state programs purposes revenue recognition company end quarter estimates applicable commercial governmental rebates paid products sold quarter nets estimated amounts total direct sales rebates estimated based terms historical experience trend analysis projected market conditions various markets served case governmental rebate programs companys payments involve interpretations relevant statutes regulations interpretations subject challenges changes interpretive guidance governmental authorities result challenge change could affect whether estimated governmental rebate amounts ultimately sufficient satisfy companys obligations additional information governmental inquiries focused part calculation rebates contained legal environmental regulatory matters footnote notes consolidated financial statements report addition possible result governmental challenges changes interpretive guidance actual rebates could materially exceed amounts accrued december taxes provided approximately billion undistributed earnings foreign subsidiaries management determined assets associated earnings permanently reinvested companys overseas operations future events require certain assets associated earnings repatriated united states additional tax provisions may necessary also regard income taxes certain companys consolidated subsidiaries manufacture pharmaceutical ingredients facilities located lowtax jurisdictions manufacturing subsidiaries sell pharmaceutical ingredients consolidated subsidiaries manufacturing final sale customers taxing authorities throughout world table contents challenge prices charged manufacturing subsidiaries management believes pricing based upon sound economic facts circumstances however successful challenge taxing authority management believes unlikely could result additional income tax payments materially excess amounts accrued intangible assets representing capitalized costs purchased goodwill patents licenses forms intellectual property totaled million december value assets subject continuing scientific medical marketplace uncertainty example marketed pharmaceutical product withdrawn market safety reasons marketing product could occur pronounced warnings amounts capitalized product may need reduced due impairment events giving rise impairment inherent risk pharmaceutical industry predicted management regularly reviews intangible assets possible impairment discussed special charges section company recognized asset impairment losses intangible assets asset impairment losses recognized intangible asset related cancer therapy drug due scientific advancements intangible asset relating trade name sun care product due marketplace competition management judgments estimates also required accounting legal regulatory matters particular company recognized estimated minimum liabilities connection certain government investigations sales marketing activities see legal environmental regulatory matters footnote notes consolidated financial statements market risk disclosures company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rates equity prices following describes nature risks foreign currency exchange risk company subsidiaries countries sales outside united states accounted approximately percent global sales virtually sales denominated currencies local country companys reported profits cash flows exposed changing exchange rates changes foreign exchange rates increased sales percent increased diluted earnings per common share date management deemed cost effective engage formulabased program hedging profits cash flows foreign operations using derivative financial instruments companys foreign subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provides level protection adverse changes exchange rates risk adverse exchange rate change also mitigated fact companys foreign operations widespread table contents addition point time companys foreign subsidiaries hold financial assets liabilities denominated currencies us dollars financial assets liabilities consist primarily shortterm thirdparty intercompany receivables payables changes exchange rates affect financial assets liabilities part however gains losses arise translation significantly affect net income occasion company used derivatives hedge specific shortterm risk situations involving foreign currency exposures however derivative transactions material interest rate equity price risk financial assets exposed changes interest rates andor equity prices debt equity securities held nonqualified trusts employee benefits assets totaled million december due longterm nature liabilities trust assets fund companys exposure market risk deemed low financial obligations exposed variability interest expense shortterm borrowings company maintains cash cash equivalent portfolio well excess amount shortterm borrowings accordingly company net exposure changes interest rates relating financial obligations company longterm debt outstanding percent decrease interest rates would change fair value debt million however company expect refund debt interest rate swaps company utilized interest rate swaps part international cash management strategy additional information see financial instruments commitments footnote notes consolidated financial statements swaps subject company moderate degree market risk company accounts swaps using fair value accounting changes fair value recorded earnings fair value swaps liability million december liability million december estimated percent change interest rate structure could change fair value swaps less million table contents cautionary factors may affect future results cautionary statements private securities litigation reform act managements discussion analysis financial condition results operations sections report written reports oral statements made time time company may contain forwardlooking statements within meaning securities litigation reform act forwardlooking statements relate expectations forecasts future events use words anticipate believe could estimate expect forecast project intend plan potential words terms similar meaning connection discussion potential future events circumstances future operating financial performance also identify forwardlooking statements fact relate strictly historical current facts particular forwardlooking statements include statements relating future actions ability access capital markets prospective products status product approvals future performance results current anticipated products sales efforts development programs expenses programs reduce expenses cost savings verp outcome contingencies litigation investigations growth strategy financial results forwardlooking statements publications may turn wrong actual results may vary materially guarantees performance scheringplough stock scheringplough assume obligation update forwardlooking statement many factors could cause actual results differ scheringploughs forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known although possible predict identify factors may include following significant portion net sales made major pharmaceutical health care products distributors major retail chains united states consequently net sales quarterly growth comparisons may affected fluctuations buying patterns major distributors retail chains trade buyers fluctuations may result seasonality pricing wholesaler buying decisions factors competitive factors including technological advances attained competitors patents granted competitors new products competitors coming market new indications competitive products generic prescription otc competition scheringploughs products mature patents expire products increased pricing pressure united states abroad managed care organizations institutions government agencies programs united states among developments consolidation among customers may increase pricing pressures may result various customers greater influence prescription decisions formulary decisions policies government laws regulations changes laws regulations affecting domestic international operations including health care reform initiatives drug importation legislation united states state federal level table contents countries well laws regulations relating trade antitrust monetary fiscal policies taxes price controls possible nationalization patent positions highly uncertain patent disputes unusual adverse result patent dispute preclude commercialization products negatively impact sales existing products result injunctive relief payment financial remedies uncertainties fda approval process regulatory approval review processes countries including without limitation delays approval new products failure meet good manufacturing practices established fda governmental authorities result delays approval products release products seizure recall products suspension revocation authority necessary production sale products fines civil criminal sanctions resolution manufacturing issues fda discussed scheringploughs ks qs ks subject substantial risks uncertainties risks uncertainties including timing scope duration resolution manufacturing issues depend ability scheringplough assure fda quality reliability manufacturing systems controls extent remedial prospective obligations undertaken scheringplough difficulties product development pharmaceutical product development highly uncertain products appear promising development may fail reach market numerous reasons may found ineffective harmful side effects clinical preclinical testing may fail receive necessary regulatory approvals may turn economically feasible manufacturing costs factors may precluded commercialization proprietary rights others efficacy safety concerns respect marketed products whether scientifically justified leading recalls withdrawals declining sales major products claritin clarinex intron pegintron rebetol capsules remicade nasonex accounted material portion scheringploughs revenues major product become subject problem loss patent protection otc availability companys product competitive product disclosed claritin current potential otc competition previously unknown side effects new effective treatment introduced generic availability competitive products product discontinued reason impact revenues could significant information important new products zetia important products pipeline may impact future revenues unfavorable outcomes government local federal domestic international investigations litigation product pricing product liability claims litigation environmental concerns could preclude commercialization products negatively affect profitability existing products materially adversely impact scheringploughs financial condition results operations contain conditions impact business operations exclusion government reimbursement programs economic factors scheringplough control including changes inflation interest rates foreign currency exchange rates table contents instability disruption destruction significant geographic region due location manufacturing facilities distribution facilities customers regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm diseases changes tax laws including changes related taxation foreign earnings changes accounting standards promulgated american institute certified public accountants financial accounting standards board sec public company accounting oversight board would require significant change scheringploughs accounting practices details discussion risks uncertainties see scheringploughs past future sec filings item quantitative qualitative disclosures market risk see market risk disclosures set forth item managements discussion analysis operations financial condition results operation table contents item financial statements supplementary data index financial statements statements consolidated operations years ended december statements consolidated cash flows years ended december consolidated balance sheets december statements consolidated shareholders equity years ended december notes consolidated financial statements independent auditors report table contents scheringplough corporation subsidiaries statements consolidated operations years ended december amounts millions except per share figures net sales cost sales selling general administrative research development income expense net special charges equity income cholesterol joint venture lossincome income taxes income taxes net lossincome diluted lossearnings per common share basic lossearnings per common share see notes consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated cash flows years ended december amounts millions operating activities net lossincome depreciation amortization accounts receivable inventories prepaid expenses assets accounts payable liabilities special charges net cash provided operating activities investing activities capital expenditures purchases investments reduction investments net net cash used investing activities financing activities cash dividends paid common shareholders common shares repurchased net change shortterm borrowings issuance longterm debt net net cash provided used financing activities effect exchange rates cash cash equivalents net increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year see notes consolidated financial statements table contents scheringplough corporation subsidiaries consolidated balance sheets december amounts millions except per share figures assets current assets cash cash equivalents shortterm investments accounts receivable less allowances inventories deferred income taxes prepaid expenses current assets total current assets property cost land buildings improvements equipment construction progress total less accumulated depreciation property net goodwill intangible assets net assets total assets table contents december liabilities shareholders equity current liabilities accounts payable shortterm borrowings current portion longterm debt us foreign state income taxes accrued compensation accrued liabilities total current liabilities longterm liabilities longterm debt deferred income taxes longterm liabilities total longterm liabilities shareholders equity preferred shares authorized shares par value issued none common shares authorized shares par value issued paidin capital retained earnings accumulated comprehensive income total less treasury shares cost total shareholders equity total liabilities shareholders equity see notes consolidated financial statements table contents scheringplough corporation subsidiaries statements consolidated shareholders equity accumulated total compre share common paidin retained treasury hensive holders amounts millions shares capital earnings shares income equity balance january comprehensive income net income foreign currency translation realized gain reclassified income net tax total comprehensive income cash dividends common shares stock incentive plans common shares repurchased balance december comprehensive income net income foreign currency translation minimum pension liability net tax realized gain reclassified income net tax total comprehensive income cash dividends common shares stock incentive plans balance december comprehensive income net loss foreign currency translation minimum pension liability net tax unrealized gain investments available sale net tax total comprehensive income cash dividends common shares stock incentive plans balance december see notes consolidated financial statements table contents notes consolidated financial statements dollars millions except per share figures summary significant accounting policies principles consolidation consolidated financial statements include scheringplough corporation subsidiaries company intercompany balances transactions eliminated certain prior year amounts reclassified conform current year presentation use estimates preparation financial statements conformity generally accepted accounting principles requires management make estimates use assumptions affect certain reported amounts disclosures actual amounts may differ cash cash equivalents cash cash equivalents include operating cash highly liquid investments generally original maturities three months less inventories inventories valued lower cost market cost determined using lastin firstout method substantial portion inventories located united states cost inventories determined firstin firstout method depreciation depreciation provided estimated useful lives properties generally use straightline method average useful lives years buildings years building improvements years equipment depreciation expense respectively foreign currency translation net assets companys foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation adjustment account included comprehensive income remaining foreign subsidiaries nonmonetary assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income exchange gains losses arising translating intercompany balances longterm investment nature recorded foreign currency translation adjustment account exchange gains losses included income table contents accumulated comprehensive income accumulated comprehensive income primarily consists accumulated foreign currency translation adjustment account unrealized gains losses securities classified statement financial accounting standards sfas purposes available sale minimum pension liability adjustment components accumulated comprehensive income december accumulated foreign currency translation accumulated unrealized gains losses investments available sale net tax minimum pension liability net tax total gross unrealized pretax gains unrealized losses immaterial gross unrealized gains losses immaterial revenue recognition revenues sale products recognized goods shipped customers reliable estimates product returns made reliable estimates product returns made business conditions permit company make reasonable estimates expected demand following approval claritin overthecounter otc product fourth quarter revenue us sales prescription form claritin recognized product used fill patient prescriptions reliable estimates product returns could made time shipment since expiration initial day period exclusivity first generic competitor otc form claritin company experienced additional privatelabel competition result revenues sales otc claritin recognized time shipment extent company make reasonable estimates product returns provisions discounts rebates recorded period related sales recorded purposes revenue recognition end quarter company estimates applicable commercial governmental rebates paid products sold reduces recorded sales estimated amounts rebates estimated based terms historical experience trend analysis projected market conditions various markets served table contents earnings per common share diluted earnings per common share computed dividing income sum weightedaverage number common shares outstanding plus dilutive effect shares issuable deferred stock units exercise stock options diluted loss per common share excludes effect shares issuable deferred stock units exercise stock options including would effect decreasing loss per share basic earnings per common share computed dividing income weightedaverage number common shares outstanding shares used calculate basic diluted earnings per common share reconciled follows shares millions average shares outstanding basic earnings per share dilutive effect options deferred stock units average shares outstanding diluted earnings per share equivalent million million million common shares issuable companys stock incentive plans excluded computation diluted earnings per share december respectively effect would antidilutive goodwill effective january company adopted sfas goodwill intangible assets sfas eliminates requirement amortize goodwill instead requires periodic testing goodwill impairment goodwill impaired written estimated fair value company performed required annual goodwill impairment tests found recorded goodwill impaired accordingly adoption sfas result adjustment recorded goodwill goodwill amortization expense diluted basic earnings per common share would unchanged goodwill amortization excluded net income pro forma basis companys goodwill primarily related animal health business intangible assets components balance sheet caption intangible assets net follows december december gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net patents licenses trademarks total intangible assets table contents intangible assets amortized straightline method respective useful lives company paid respectively patent licensing rights costs amortized approximately nine years residual value intangible assets estimated zero amortization expense related intangible assets respectively intangible assets reviewed determine recoverability comparing carrying values expected undiscounted future cash flows events circumstances warrant review full year amortization expense next five years estimated approximately per year based intangible assets recorded december accounting stockbased compensation company accounts stock compensation arrangements using intrinsic value method intrinsic value method difference amount employee pay company stock acquired companys incentive plans stocks fair value date grant charged expense since employees must pay company grantdate fair value stock options expense recorded stock options alternatively since employees pay stock issued deferred stock units granted grant date fair value recorded expense following table reconciles net lossincome lossearnings per common share eps reported pro forma net lossincome eps company expensed grantdate fair value stock options deferred stock units permitted sfas accounting stockbased compensation pro forma amounts may representative initial impact adopting sfas since amended permits alternative methods adoption net lossincome reported add back expense included reported net income deferred stock units net tax deduct pro forma expense stock options deferred stock units charged net income net tax pro forma net lossincome using fair value method diluted lossearnings per share diluted lossearnings per share reported pro forma diluted lossearnings per share using fair value method basic lossearnings per share basic lossearnings per share reported pro forma basic lossearnings per share using fair value method table contents weightedaverage fair value options granted respectively fair values estimated using blackscholes option pricing model based following assumptions dividend yield volatility riskfree interest rate expected term options years recently issued accounting standards november fasb issued fasb interpretation guarantors accounting disclosure requirements guarantees including indirect guarantees indebtedness others normal course business company issue guarantees third parties accordingly interpretation effect companys financial statements april fasb issued sfas amendment statement derivative instruments hedging activities adoption sfas effect companys financial statements may fasb issued sfas accounting certain financial instruments characteristics liabilities equity requires certain financial instruments classified liability asset circumstances adoption sfas effect companys financial statements december fasb issued fasb interpretation revised consolidation variable interest entities fin adoption fin effect companys financial statements january fasb issued staff position fas titled accounting disclosure requirements related medicare prescription drug improvement modernization act fsp act signed law december introduces prescription drug benefit medicare well federal subsidy certain conditions sponsors retiree health care benefit plans presently authoritative guidance accounting subsidy issued company elected onetime deferral accounting effects act permitted fsp deferral continues apply authoritative guidance accounting federal subsidy issued special charges components special charges follows employee termination costs asset impairment losses litigation charges consent decree charge table contents employee termination costs august company announced global workforce reduction initiative first phase initiative voluntary early retirement program united states program eligible employees united states december elect early retirement receive enhanced retirement benefit approximately employees elected retire program approximately employees retired near yearend approximately employees staggered retirement dates future total cost program estimated comprised increased pension costs increased postretirement health care costs vacation payments costs related accelerated vesting stock grants employees staggered retirement dates future amounts recognized special charge employees remaining service periods delayed expense recognition follows guidance sfas accounting costs associated exit disposal activities amounts recognized program amounts expected recognized respectively asset impairment losses asset impairment losses recognized accordance sfas goodwill intangible assets sfas accounting impairment disposal long lived assets asset impairment losses related following company ceased production certain products produced one manufacturing sites operating fda consent decree company also announced closure manufacturing site england manufacturing site england substantially ceased sales affected products material asset impairment loss based discounted cash flows recognized related facilities equipment two sites company ceased marketing licensed cancer therapy drug sold countries outside united states sales product declined material introduction competing products resulted decline market share companys drug point management concluded longer practical continue participate marketplace asset impairment loss based discounted cash flows recognized related intangible asset one companys sun care brands competes highend segment overall sun care market two large cosmetics companies entered market segment sales companys brand declined company acquired brand portion purchase price allocated trade name based upon fair value time company performs periodic reviews values assigned intangible assets connection reviews impairment loss related trade name recognized based discounted cash flows reflects change market conditions since brand acquired sales sun care brand material table contents litigation charges litigation reserves increased respectively primarily result investigations companys sales marketing practices see legal environmental regulatory matters footnote additional information consent decree charge provision recognized payments federal government consent decree see consent decree footnote additional information summary selected special charges following summarizes activity accounts related employee termination costs asset impairment losses employee asset termination impairment costs losses special charges impairment writeoff credit retirement benefit plan liability cash disbursement special charges accrual balance dec balance december employee termination costs represents value stock grants distributed yearend severance accrued vacation payments paid financial instruments commitments sfas amended requires derivatives recorded balance sheet fair value statement also provides effective portion qualifying cash flow hedges recognized income hedged item affects income changes fair value derivatives qualify fair value hedges along change fair value hedged risk recognized occur changes fair value derivatives qualify hedge treatment well ineffective portion qualifying hedges recognized income occur risks policy objectives company exposed market risk primarily changes foreign currency exchange rates lesser extent interest rate equity price changes time time company hedge selective foreign currency risks derivatives generally however management deemed cost effective engage formulabased program hedging profits cash flows foreign operations using derivative financial instruments companys foreign subsidiaries purchase significant quantities inventory payable us dollars managing level inventory related payables rate inventory turnover provides level protection adverse changes exchange rates furthermore risk adverse exchange rate change mitigated fact companys foreign operations widespread limited basis company hedge selective exposures interest rate risks table contents company mitigates credit risk derivative instruments dealing counterparties considered financially sound accordingly company anticipate loss nonperformance company enter derivative instruments generate trading profits table presents carrying values estimated fair values companys financial instruments including derivative financial instruments estimated fair values determined based market prices available dealer quotes december december carrying estimated carrying estimated value fair value value fair value assets cash cash equivalents shortterm investments longterm investments interest rate swap contracts liabilities shortterm borrowings current portion longterm debt longterm debt financing instruments interest rate swap contracts longterm investments longterm investments included noncurrent assets primarily consist debt equity securities held nonqualified trusts fund longterm employee benefit obligations included liabilities consolidated balance sheets assets used fund related liabilities longterm investments primarily classified available sale carried fair value realized gains sale securities classified available sale proceeds sales totaled respectively realized gains recorded income expense net interest rate swap contracts assets hedge variable rate risk associated variable rate time deposit purchased company entered interest rate swap matured november terms swap company received fixed rate approximately percent paid threemonth libor rate notional amount swap designated cash flow hedge effective portion swap deferred transaction hedged recorded earnings interest rate swaps maturity value swaps fair value december table contents liabilities company utilized interest rate swaps part international cash management strategy notional principal arrangement notional principal arrangement arrangements year terms december arrangements provide payment interest based upon libor receipt interest based upon annual election various floating rates result company remains subject moderate degree market risk maturity swaps swaps designated hedging instruments accordingly changes fair value recorded earnings annual net cash flows payments receipts interest rate swap contracts material net asset liability interest rate swaps recorded current assets accrued liabilities applicable fair value swaps liability december company triggered credit rating downgrade provisions swap arrangements result counterparty terminate swaps impact terminating swaps material borrowings general shortterm borrowings consist commercial paper issued united states bank loans notes payable connection companys purchase research office facility company issued note paid full march imputed interest rate note percent commercial paper outstanding december respectively weightedaverage interest rate shortterm borrowings december percent percent respectively november company issued aggregate principal amount percent senior unsecured notes due aggregate principal amount percent senior unsecured notes due interest payable semiannually net proceeds offering upon issuance notes rated moodys investors service inc moodys creditwatch negative implications standard poors rating services sp interest rates payable notes subject adjustment follows rating assigned notes moodys changes one ratings set forth interest rate payable series notes increase additional interest rate set forth similarly rating assigned notes sp changes one ratings set forth interest rate payable series notes increase additional interest rate set forth additional interest rate moodys rating sp rating baa bbb baa bbb baa bbb ba bb event interest rate notes increase percent initial coupon rates percent percent respectively either moodys sp table contents subsequently upgrades ratings interest rates correspondingly reduced percent percent respectively furthermore interest rate payable particular series notes return percent percent respectively rate adjustment provisions permanently cease apply following downgrade moodys sp respectively moodys sp raise rating respectively better notes redeemable whole part companys option time redemption price equal greater percent principal amount notes sum present values remaining scheduled payments principal interest discounted using rate treasury notes comparable remaining terms plus basis points notes basis points notes fair value combined notes december company three revolving credit facilities totaling recently negotiated facility september day credit facility three major financial institutions drawn united states facility matures september facilities syndicate financial institutions provide drawn united states may repayment due may second multicurrency facility drawn united states internationally maturity date may facilities available general corporate purposes considered support companys commercial paper borrowings facilities require compensating balances however nominal commitment fee paid december funds drawn facilities addition companys foreign subsidiaries approximately available unused lines credit various financial institutions december credit ratings changes credit ratings december sp lowered companys corporate credit longterm debt ratings said outlook ratings negative noting weakening companys intron franchise expected declines earnings cash flows change companys shortterm corporate credit commercial paper rating lowered july january sp placed companys corporate credit rating shortterm credit rating senior unsecured debt rating creditwatch negative implications february sp downgraded companys senior unsecured debt ratings time sp also lowered companys shortterm corporate credit commercial paper rating sp removed company creditwatch however outlook remains negative october moodys lowered companys corporate credit rating lowered commercial paper rating p p following rating action moodys removed company watchlist revised rating outlook stable negative moodys also stated credit rating assumed modest outflows settle outstanding litigation acquisitions large payment associated litigation proceedings acquisition activity could place pressure rating andor outlook november fitch ratings fitch downgraded companys senior unsecured bank loan ratings commercial paper rating f f table contents companys rating outlook remained negative announcing downgrade fitch noted sales decline companys leading product franchise intron franchise greater anticipated concerned total company growth reliant performance two key growth drivers zetia remicade near term table contents financing instruments subsidiary company issued equitytype securities securities certain put call features put call features obligation included longterm liabilities december securities bore liborbased yield substantially fixed november december rate percent company exercised call option fully redeemed securities november commitments total rent expense amounted future minimum rental commitments noncancelable operating leases december range aggregate minimum lease obligations due thereafter december company commitments totaling related capital expenditures made insurance coverage company maintains insurance coverage deductibles selfinsurance management believes adequate needs current circumstances coverage reflects market conditions including cost availability existing time written relationship insurance coverage selfinsurance varies accordingly result recent external events availability insurance become restrictive management considers impact changes continually assesses best way provide insurance needs future company selfinsures higher proportion risk past especially relates products liability income expense net components income expense net follows interest cost incurred less amount capitalized construction interest expense interest income foreign exchange gains losses net total net includes gain sale us marketing rights suboxone subutex cash paid interest net amounts capitalized respectively table contents shareholders equity summary treasury share transactions follows shares millions share balance january shares issued stock incentive plans purchase treasury shares share balance december company preferred share purchase rights outstanding attached presently trade companys common shares exercisable rights become exercisable person group acquires percent companys common stock announces tender offer completed would result ownership person group percent companys common stock person group acquire percent companys outstanding common stock merger business combination transaction right entitle holder acquirer purchase common shares scheringplough market value twice exercise price right exercise price rights following acquisition person group beneficial ownership percent less percent companys common stock board directors may call exchange rights rights owned acquirer whole part exchange ratio one common share one two hundredth share series junior participating preferred stock per right also prior acquisition person group beneficial ownership percent companys common stock rights redeemable per right option board directors rights expire july unless earlier redeemed exchanged board directors also authorized reduce percent thresholds referred less greater sum percent largest percentage outstanding shares common stock known company beneficially owned person group affiliated associated persons ii percent except following acquisition person group beneficial ownership percent companys common stock reduction may adversely affect interests holders rights equity income cholesterol joint venture company merck co inc merck agreements jointly develop market zetia ezetimibe oncedaily monotherapy coadministration zetia statins ezetimibe oncedaily fixedcombination tablet simvastatin zocor mercks cholesterolmodifying medicine agreements also involve development marketing oncedaily fixedcombination tablet containing claritin singulair singulair mercks oncedaily leukotriene receptor antagonist treatment asthma seasonal allergic rhinitis january scheringploughmerck pharmaceuticals reported results phase iii clinical trials fixedcombination tablet containing claritin singulair demonstrate sufficient added benefits treatment seasonal allergic rhinitis agreements generally provide equal sharing development costs copromotion approved products company united states countries world except japan japan agreement exists general copromotion provides table contents company provide equal physician marketing efforts company bear cost sales force marketing products general agreement provides venture operate virtual mode maximum degree possible relying respective infrastructures two companies however companies agreed share certain costs costs limited portion costs manufacturing cost specialty sales force certain specially identified promotion costs noted company incurs substantial costs selling costs reflected equity income cholesterol joint venture borne entirely company agreements provide jointly owned facilities products resulting collaboration manufactured facilities owned either merck company company earned milestone relates certain european approvals zetia certain conditions merck could pay additional milestones company totaling prior venture research development phase companys share research development expense respectively reported research development statements consolidated operations venture moved beyond research development phase zetia launched late us marketing application combination ezetimibesimvastatin submitted fda september reflect ventures first full year commercial operations company adopted equity method accounting effective beginning method company records share operating profits less share research development costs equity income cholesterol joint venture statements consolidated operations prior year amounts affected equity income cholesterol joint venture year ended december included amount companys share operating profits milestone receipt less share research development costs stock incentive plans terms companys stock incentive plan approved companys shareholders million companys common shares may granted stock options awarded deferred stock units officers certain employees company december december million options deferred stock units remain available future year grants stock incentive plan option exercise prices equal market price common shares grant dates options expire later years date grant standard options granted prior generally one year vesting term option grants vest longer periods ranging three nine years deferred stock units payable equivalent number common shares shares distributable single installment three five equal annual installments generally commencing one year date award table contents following table summarizes stock option activity past three years current prior plans approved companys shareholders weighted weighted weighted number average number average number average exercise exercise exercise number options millions options price options price options price outstanding january granted exercised canceled expired outstanding december exercisable december summarized information stock options outstanding exercisable december follows number options millions outstanding exercisable weighted average weighted weighted number remaining average number average term exercise exercise exercise price range options years price options price company awarded deferred stock units totaling million million million respectively inventories yearend inventories consisted following finished products goods process raw materials supplies total inventories inventories valued lastin firstout basis comprised approximately percent percent total inventories december respectively estimated replacement cost total inventories december respectively retirement plans postretirement benefits company defined benefit pension plans covering eligible employees united states certain foreign countries company provides post retirement health care benefits eligible us retirees dependents measurement date majority plans december table contents net pension expense compared net pension expense increase principally due costs associated voluntary early retirement program see special charges footnote additional information estimated onehalf percent reduction expected long term rate return consolidated plan assets would increase pension expense approximately estimated onehalf percent reduction discount rate would increase pension expense approximately also december company unrecognized net pension loss gains losses arise primarily plan assets earning less longterm expected rate return changes pension discount rates gains future offset net unrecognized loss amortization losses would ultimately increase annual pension expense approximately components net pension postretirement benefits expense income follows postretirement retirement plans health care benefits service cost interest cost expected return plan assets amortization net termination benefits curtailment settlement net pension postretirement benefits expense income components changes benefit obligations follows postretirement retirement plans health care benefits benefit obligations january service cost interest cost assumption changes effects exchange rate changes benefits paid actuarial losses plan amendments termination benefits curtailment settlement benefit obligations december benefit obligations overfunded plans benefit obligations underfunded plans termination benefits curtailment settlement costs primarily relate matters discussed special charges footnote table contents components changes plan assets follows postretirement retirement plans health care benefits fair value plan assets primarily stocks bonds january actual gain loss plan assets contributions effects exchange rate changes benefits paid fair value plan assets december plan assets overfunded plans plan assets underfunded plans fair value plan assets domestic pension plans december respectively addition plan assets indicated december securities respectively held nonqualified trusts designated provide pension benefits certain underfunded plans december accumulated benefit obligation retirement plans respectively aggregated accumulated benefit obligation fair value plan assets retirement plans accumulated benefit obligation excess plan assets respectively december respectively december presently company anticipate making contributions fund us retirement plan postretirement health care plan following reconciliation funded status plans companys balance sheet postretirement health retirement plans care benefits benefit obligations excess plan assets unrecognized net transition assets unrecognized prior service costs unrecognized net actuarial loss net assets december amounts recognized balance sheet consist postretirement health retirement plans care benefits prepaid benefit cost accrued benefit cost intangible assets accumulated comprehensive income net assets december table contents company recognized additional minimum pension liability respectively primarily related domestic retirement plans resulted adjustment accumulated comprehensive income net tax respectively consolidated weightedaverage assumptions used determine benefit obligations december postretirement retirement plans health care benefits discount rate rate increase future compensation na na consolidated weightedaverage assumptions used determine net cost years ended december postretirement retirement plans health care benefits discount rate longterm expected rate return plan assets rate increase future compensation na na longterm expected rate return plan assets domestic retirement plans percent percent years ended december respectively longterm expected rate return plan assets derived proportionally return assumptions determined major asset classes principally equities fixed income real estate return expectations asset classes based largely assumptions economic growth inflation supported longterm historical data weightedaverage assumed health care cost inflation rate used postretirement measurement purposes percent trending percent percent increase assumed health care cost trend rate would increase combined postretirement service interest cost postretirement benefit obligation percent decrease assumed health care cost trend rate would decrease combined postretirement service interest cost postretirement benefit obligation medicare prescription drug improvement modernization act act signed law united states company elected defer accounting effect act permitted fasb staff position fas therefore benefit obligations reported herein companys postretirement benefit plans reflect impact act specific authoritative guidance accounting federal subsidy related act pending issued could require company change previously reported information table contents us plan assets fair value asset allocation us retirement plan december target allocation follows percentage plan target assets december allocation asset category equity securities debt securities real estate total asset allocation postretirement health care benefit trusts december target allocation follows percentage plan target assets december allocation asset category equity securities debt securities total companys investments related plans broadly diversified consisting primarily equities fixed income securities objective generating longterm investment returns consistent acceptable level overall portfolio market value risk company defined contribution profitsharing plan covering substantially fulltime domestic employees completed one year service annual contribution determined formula based companys income shareholders equity participants compensation profitsharing expense totaled respectively profit sharing contribution determined formula described company longer make contributions plan effective income taxes us foreign operations contributed income income taxes follows united states foreign total lossincome income taxes table contents components income tax expensebenefit follows current federal foreign state total current deferred federal state foreign total deferred total income tax expense difference income taxes based us statutory tax rate companys income tax expense due following income tax expensebenefit us statutory tax rate increase decrease taxes resulting lower rates jurisdictions net nondeductible litigation reserve reserve tax litigation research tax credit state income tax permanent differences net income tax expense effective tax rate lower rates jurisdictions net primarily attributable certain employment capital investment actions taken company result income manufacturing activities jurisdictions subject lower tax rates due tax loss company recorded tax refund receivable december december company total deferred tax assets respectively deferred tax liabilities respectively valuation allowances december valuation allowances significant december significant deferred tax assets december operating costs employee termination costs currently deductible tax purposes totaled respectively significant deferred tax liabilities december depreciation differences respectively retirement plans respectively deferred taxes provided undistributed earnings foreign subsidiaries considered permanent investments december approximated determining tax liability would arise earnings remitted practicable table contents net consolidated income tax payments respectively december us internal revenue service irs completed examination companys tax returns years unresolved issues outstanding years irs examination years expected completed time anticipated irs commence examination years see legal environmental regulatory matters footnote regarding tax matter company believes litigation probable consent decree may company announced reached agreement fda consent decree resolve issues involving companys compliance current good manufacturing practices cgmp certain manufacturing facilities new jersey puerto rico us district court district new jersey approved entered consent decree may terms consent decree company agreed pay total us government two equal installments first installment paid may second installment paid may previously reported company accrued provision consent decree fourth quarter consent decree requires company complete number actions event certain actions agreed upon consent decree satisfactorily completed time fda may assess payments deadline missed consent decree required company develop submit fdas concurrence comprehensive cgmp work plans companys manufacturing facilities new jersey puerto rico covered decree company received fda concurrence proposed cgmp work plans may cgmp work plans contain number significant steps whose timely satisfactory completion subject payments thousand per business day deadline missed payments may exceed years payments subject overall cap connection discussions fda regarding companys cgmp work plans pursuant terms decree company fda entered letter agreement dated april letter agreement company fda agreed extend six months time period company may incur payments described respect certain significant steps whose proposed due dates december letter agreement increase yearly overall caps payments described addition decree requires company complete programs revalidation finished drug products bulk active pharmaceutical ingredients manufactured covered manufacturing facilities company required consent decree complete revalidation programs bulk active pharmaceutical ingredients september finished drugs december general timely satisfactory completion revalidations subject payments thousand per business day deadline missed subject caps described however product scheduled revalidation certified validated last date validation schedule fda may table contents assess payment percent net domestic sales uncertified product validation certified general product scheduled revalidation consent decree certified within six months scheduled date company must cease production product certification obtained completion significant steps work plans completion revalidation programs subject thirdparty expert certification must accepted fda consent decree provides company believes may able meet deadline company right upon showing good cause request extensions deadlines connection cgmp work plans revalidation programs however guarantee fda grant requests although company believes made significant progress meeting obligations consent decree possible company may fail complete significant step revalidation prescribed deadline third party expert may certify completion significant step revalidation fda may disagree experts certification significant step revalidation case possible fda may assess payments described company would expense payments assessed decree incurred also noted legal environmental regulatory matters footnote company received notice false claims complaint brought individual purporting act behalf us government approximately pharmaceutical companies alleging pharmaceutical companies defrauded united states made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices company defendants filed motion dismiss action segment information company three reportable segments prescription pharmaceuticals consumer health care animal health segment sales profit data follow consistent companys current management reporting structure established second quarter prior period information presented herein restated comparable basis prescription pharmaceuticals segment discovers develops manufactures markets human ethical pharmaceutical products consumer health care segment develops manufactures markets otc foot care sun care products animal health segment discovers develops manufactures markets animal health products net sales segment year ended december prescription pharmaceuticals consumer health care animal health consolidated net sales table contents profit segment year ended december prescription pharmaceuticals consumer health care animal health corporate consolidated lossprofit tax corporate includes charges related voluntary early retirement program see special charges footnote additional information estimated charges relate reportable segments follows prescription pharmaceuticals consumer health care animal health corporate corporate also includes provisions increase litigation reserves asset impairment charges interest income expense foreign exchange gains losses headquarters expenses miscellaneous items accounting policies used segment reporting described summary significant accounting policies net sales major therapeutic category antiinfective anticancer allergy respiratory cardiovasculars dermatologicals pharmaceuticals prescription pharmaceuticals otc includes otc claritin sales respectively foot care sun care consumer health care animal health consolidated net sales company subsidiaries countries outside united states sales outside united states comprised percent consolidated net sales percent percent single foreign country except france japan italy accounted percent consolidated net sales past three years france accounted percent percent percent consolidated net sales respectively japan accounted percent percent percent consolidated net sales respectively italy accounted percent percent percent consolidated net sales respectively table contents net sales geographic area united states europe canada latin america pacific area asia consolidated net sales net sales presented geographic area companys customers located percent percent percent respectively consolidated net sales made mckesson corporation major pharmaceutical health care products distributor also percent percent percent respectively consolidated net sales made amerisourcebergen corporation major pharmaceutical health care products distributor longlived assets geographic location united states ireland singapore puerto rico total longlived assets shown geographic location primarily property sales products comprising percent companys us international sales year ended december follows us international intron franchise clarinex otc claritin remicade company disaggregate assets segment basis internal management reporting therefore information presented table contents legal environmental regulatory matters background company responsibilities environmental cleanup various state local federal laws including comprehensive environmental response compensation liability act commonly known superfund several superfund sites equivalent sites state law company alleged potentially responsible party prp company estimates obligations cleanup costs superfund sites based information obtained federal environmental protection agency epa equivalent state agency andor studies prepared independent engineers probable costs paid prps company records liability environmental assessments andor cleanup probable loss incurred amount reasonably estimated company also involved various claims legal proceedings nature considered normal business including product liability cases company adjusts accrued liabilities reflect current best estimate probable loss exposure best estimate determinable company accrues minimum amount within probable range liability recorded liabilities matters december related expenses incurred months ended december material expected insurance recoveries considered determining costs environmentalrelated liabilities management believes except matters discussed remainder section remote time material liability excess amounts accrued incurred respect matters discussed remainder section except noted practicable estimate range reasonably possible loss reserve included financial statements resolution matters discussed remainder section individually aggregate could material adverse effect companys results operations financial condition management reviews status matters discussed remainder section ongoing basis time time may settle otherwise resolve terms conditions management believes best interests company company aware settlements matters types set forth remainder section particular investigations frequently involve fines andor penalties material financial condition results operations entity entering settlement assurances company prevail matters settlements reached acceptable terms including scope release provided amounts exceed amounts reserved even acceptable settlement reached assurance investigations litigations commenced raising similar type issues potentially exposing company additional material liabilities company predict timing resolution matters outcomes table contents environmental residents vicinity publicly owned wastewater treatment plant barceloneta puerto rico filed two lawsuits plant owner operator numerous companies discharge plant including subsidiary company damages injunctive relief relating odors allegedly coming plant connecting sewers one lawsuits class action claiming damages trial date set cases matter submitted mediation november received general notice potential liability epa addressed arnoscholls adhesive tapes inc former subsidiary company relating lake culmet cluster site chicago illinois several hundred potentially responsible parties site scheringplough responded information request new jersey department environmental protection relating contamination lower passaic river basin scheringplough denied connection contamination late september department directed prps contaminated sites assess restore natural resource damage lower passaic river basin department name scheringplough prp however department sent scheringplough letter received september stating company may legally responsible damages natural resources state department adopted regulations covering liability calculated making difficult accurately predict ultimate extent companys exposure patent matters claritin patents february geneva pharmaceuticals inc geneva submitted abbreviated new drug application anda us fda seeking market generic claritin tablets expiration companys desloratadine compound patent company believes protects claritin geneva alleged desloratadine compound patent invalid patent material companys business march company filed suit federal court seeking ruling genevas anda submission constitutes infringement companys desloratadine compound patent challenge patent without merit addition geneva following companies made similar anda submissions generic claritin tablets zenith goldline pharmaceuticals mylan pharmaceuticals inc teva pharmaceuticals usa inc teva ranbaxy pharmaceuticals inc ranbaxy genpharm incorporated l perrigo company perrigo following companies made similar anda submissions generic claritin syrup teva copley pharmaceuticals inc novex pharma alpharma uspd inc taro pharmaceuticals usa inc morton grove pharmaceuticals inc perrigo andrx pharmaceuticals llc andrx impax laboratories inc impax made similar anda submissions generic claritind hour claritind hour formulations ranbaxy made similar anda submission generic claritind hour formulation esi lederle inc lederle subsidiary wyeth made similar anda submission generic claritin reditab formulation following companies submitted paper new drug applications paper ndas section b federal food drug cosmetic act seeking market generic otc form claritin prior expiration companys desloratadine compound patent whitehallrobins healthcare division wyeth otc reditab formulation mcneil consumer healthcare mcneil otc tablets perrigo otc tablets case company filed suit federal court seeking ruling applicable anda paper nda submission proposed marketing generic prescription otc product constitutes infringement companys desloratadine compound patent challenge table contents patent without merit august federal district court new jersey ruled motions summary judgment finding certain claims desloratadine compound patent anticipated prior patent thus valid august district courts decision sustained appellate court october appellate court denied companys petition rehearing rulings actions defendants infringement desloratadine compound patent manufacturers loratadine proceed company also asserted impaxs andrxs andas generic claritind hour formulations infringe companys patent covering claritind hour formulation october company settled litigation impax andrx licensed patent rebetol patents august geneva pharmaceuticals technology corp geneva pharmaceuticals three rivers pharmaceuticals llc three rivers january teva submitted separate andas fda seeking market generic forms mg rebetol ribavirin capsules united states expiration companys patents covering ribavirin formulations geneva pharmaceuticals three rivers teva asserted infringe companys rebetol patents andor patents invalid rebetol patents material companys business september october march company filed suits federal court seeking rulings anda submissions geneva pharmaceuticals three rivers teva respectively constitute infringement companys patents challenges companys patents without merit company entered separate licensing agreements three rivers geneva pharmaceuticals teva settled patent litigation company three rivers teva geneva pharmaceuticals granted three rivers geneva pharmaceuticals teva nonexclusive nonsublicensable license companys us ribavirin patents agreements subject dismissal three rivers geneva pharmaceuticals tevas reported patent litigation ribapharm inc subsidiary valeant pharmaceuticals international ribapharm litigation dismissed upon defendants motion summary judgment july ribapharm appealed summary judgment decision ribapharm also petitioned fda deny approval three rivers geneva pharmaceuticals teva products fda acted ribapharm petition date report prime pac prrs patent january jury found companys prime pac prrs porcine respiratory reproductive syndrome vaccine infringed patent owned boehringer ingelheim vetmedica inc injunction issued august barring sales companys vaccine companys posttrial motions either reversal jurys verdict new trial denied september company appealed verdict affirmed appellate court february litigation damages phase case ongoing trial determine damages scheduled may investigations pennsylvania investigation october company received subpoena us attorneys office eastern district pennsylvania pursuant health insurance portability accountability act concerning companys contracts pharmacy benefit managers pbms managed care organizations provide disease management services connection marketing pharmaceutical products appears subpoena one number addressed industry participants part inquiry among things pharmaceutical marketing practices governments inquiry focused among things whether companys disease management marketing table contents programs arrangements comply federal health care laws whether value disease management programs marketing programs arrangements included calculation rebates government company cooperating investigation march us attorneys office began issuing grand jury subpoenas grand jury investigation appears focused one transactions managed care organizations government believes company offered provided deeply discounted pharmaceutical products known nominally priced products generally excluded medicaid rebate calculations free discounted disease management services marketing programs arrangements delivered value order place retain one companys major pharmaceutical products managed care organizations formulary grand jury appears investigating among things whether transactions described conduct relating thereto violated federal antikickback statutes ii whether value items services described included companys calculation medicaid rebates outcome investigations could include commencement civil andor criminal proceedings involving substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs company predict whether investigations affect marketing practices sales third quarter company increased litigation reserves related investigation investigations described us attorneys office district massachusetts increase reserves reflects maturing discussions offices particularly eastern district pennsylvania adjustment companys estimate minimum liability relating investigations compliance us generally accepted accounting principles gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made fourth quarter company increased litigation reserves matters company predict timing resolution matters company notes total reserves reflect estimate final settlement adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company awp investigations company responding investigations department health human services department justice committee energy commerce us house representatives certain states certain industry company practices regarding average wholesale price awp investigations include department justice review merits federal action filed private entity behalf united states us district court southern district florida well investigation us attorneys office district massachusetts regarding inter alia whether awp set pharmaceutical companies certain drugs improperly exceeds average prices paid dispensers consequence results unlawful inflation certain government drug reimbursements based awp march company received subpoena massachusetts attorney generals office seeking documents concerning use awp pricing andor marketing practices company cooperating investigations outcome investigations could include imposition substantial fines penalties injunctive administrative remedies massachusetts investigation us attorneys office district massachusetts also investigating whether companys sales product manufactured private label arrangement managed care organization included companys medicaid best price calculations early november company served two table contents additional grand jury subpoenas us attorney district massachusetts among information subpoenas seek broad range information concerning companys sales marketing clinical trial practices programs respect intron rebetron temodar companys sales marketing contacts managed care organizations doctors companys offering provision grants honorariums items services value managed care organizations physician groups doctors educational institutions company understands investigation focused whether certain sales marketing clinical trial practices conduct related thereto certain instances relate use one mentioned products indications fda approval obtained socalled offlabel uses violation federal laws regulations respect offlabel promotional activities investigation also appears focus whether drug samples clinical trial grants items services value given providers incentivize prescribe one abovementioned products including offlabel uses violation federal health care antikickback laws company implemented certain changes sales marketing clinical trial practices continuing review practices ensure compliance relevant laws regulations company cooperating investigations future sales intron rebetron temodar may adversely affected company time predict ultimate impact sales outcome investigations could include commencement civil andor criminal proceedings involving imposition substantial fines penalties injunctive administrative remedies including exclusion government reimbursement programs third quarter company increased litigation reserves related investigations us attorneys office district massachusetts described paragraph paragraph immediately preceding investigation described us attorneys office eastern district pennsylvania increased litigation reserves reflect adjustment companys estimate minimum liability relating investigations compliance gaap gaap companies required estimate recognize minimum liability loss probable better estimate loss made fourth quarter company increased litigation reserves matters company notes total reserves reflect estimate final settlement adjudication matters could possibly less could materially exceed aggregate liability accrued company could materially adverse effect operations financial condition company company predict timing resolution matters outcomes reported k filed may scheringplough disclosed connection abovedescribed investigations us attorneys office district massachusetts sales marketing clinical trial practices among matters may schering corporation wholly owned significant operating subsidiary scheringplough received letter boston target letter office advising schering corporation including subsidiaries divisions target federal criminal investigation respect four areas providing remuneration drug samples clinical trial grants items services value managed care organizations physicians others induce purchase schering pharmaceutical products payment made federal health care programs table contents sale misbranded unapproved drugs company understands mean drugs promoted indications approval us fda obtained socalled offlabel uses submitting false pharmaceutical pricing information government purposes calculating rebates required paid medicaid program failing include prices products repackaging arrangement managed care customer well prices free nominally priced goods provided customer induce purchase schering products document destruction obstruction justice relating governments investigation target defined department justice guidelines person prosecutor grand jury substantial evidence linking commission crime judgment prosecutor putative defendant us attorneys manual section consumer products matter us department justice antitrust division investigating whether companys consumer products division entered agreement another company lower commission rate consumer products broker february antitrust division served grand jury subpoena company seeking documents first time company cooperating investigation nitrodur investigation august company received civil investigative subpoena issued office inspector general us department health human services seeking documents concerning companys classification nitrodur medicaid rebate purposes companys use nominal pricing bundling product sales company cooperating investigation appears subpoena one number addressed pharmaceutical companies concerning inquiry issues relating payment government rebates securities class action litigation february company stated press release fda conducting inspections companys manufacturing facilities new jersey puerto rico issued reports citing deficiencies concerning compliance current good manufacturing practices primarily relating production processes controls procedures next day february lawsuit filed us district court district new jersey company certain named officers alleging violations sections b securities exchange act rule b promulgated thereunder additional lawsuits tenor followed complaints consolidated one action us district court district new jersey lead plaintiff florida state board administration appointed court july october consolidated amended complaint filed alleging violations described second sentence paragraph purporting represent class shareholders purchased shares company stock may february companys motion dismiss consolidated amended complaint denied may october court certified shareholder class discovery ongoing addition lawsuits described immediately preceding paragraph two lawsuits filed us district court district new jersey two lawsuits filed new table contents jersey state court company nominal defendant certain officers directors former director seeking damages behalf company including disgorgement trading profits made defendants allegedly obtained basis material nonpublic information complaints four lawsuits relate issues described companys february press release allege failure disclose material information breach fiduciary duty directors one federal court lawsuits also includes allegations related investigations us attorneys offices eastern district pennsylvania district massachusetts ftcs administrative proceeding company lawsuit state texas warrick pharmaceuticals warrick companys generics subsidiary described herein lawsuits shareholder derivative action purports assert claims behalf company demand made board directors decision made whether company pursue claims august plaintiffs new jersey state court shareholder derivative actions moved dismiss voluntarily complaints actions motions granted two shareholder derivative actions pending us district court district new jersey consolidated one action early stages january company received demand letter dated december law firm involved derivative actions described behalf shareholder also involved derivative actions demanding board directors bring claims behalf company based allegations substantially similar alleged derivative actions january board directors adopted board resolution establishing evaluation committee consisting three directors investigate review analyze facts circumstances surrounding allegations made demand letter consolidated amended derivative action complaint described reserving full board authority discretion exercise business judgment respect proper disposition demand committee engaged independent outside counsel advise issued report findings investigation independent directors board late october report determined shareholder demand refused finding liability part officers directors november full board adopted recommendation evaluation committee august prescription access litigation project pal bostonbased group formed litigate drug companies issued press release stating pal members filed lawsuit new jersey state court company december company served amended complaint case suit pal purports class action alleges among things companys directtoconsumer advertising falsely depicts benefits claritin violation new jersey consumer fraud act february company filed motion dismiss case may court dismissed complaint entirety failure state claim plaintiffs appeal denied new jersey state court plaintiffs requested new jersey supreme court hear case request denied ending litigation company defendant number purported nationwide state class action lawsuits plaintiffs seek refund purchase price laxatives phenylpropanolaminecontaining coughcold remedies ppa products purchased pharmaceutical manufacturers codefendants lawsuits general plaintiffs claim would purchased would paid less products known certain defects medical risks attendant use litigation claims relating companys ppa products courts national class action suit several state class action table contents suits denied certification dismissed suits similar application dismiss new jersey remaining statewide class action suit involving company pending approximately individual lawsuits relating laxative products ppa products recalled albuterolvancerilvancenase inhalers also pending company seeking recovery personal injuries death number lawsuits punitive damages claimed march company served putative class action complaint filed us district court new jersey alleging company richard jay kogan resigned chairman board november retired chief executive officer president director company april companys employee savings plan plan administrator breached fiduciary obligations certain participants plan allegations primarily relate disclosures companys good manufacturing practices issues discussed earlier securities class action litigation section relation companys disclosures consent decree fda related matters disclosures meetings investors week september communications discussed sec inquiry related litigation may company served second putative class action complaint filed court allegations nearly identical complaint filed march october consolidated amended complaint filed names additional defendants following directors eugene mcgrath donald miller carl mundy patricia russo kathryn turner two former directors james wood regina herzlinger corporate officers consolidated amended complaint also contains allegations associated boston target letter described investigations section footnote company filed motion dismiss complaint august lawsuit filed new jersey superior court chancery division union county served company nominal defendant companys outside directors alleging breach fiduciary duty directors relating companys receipt boston target letter described investigations section footnote action temporarily stayed pending adjudication separate related action framed shareholder request access companys books records seeking documents information relating massachusetts investigation antitrust ftc matters company defendant numerous antitrust actions commenced starting state federal courts independent retail pharmacies chain retail pharmacies consumers plaintiffs allege price discrimination andor conspiracy company defendants restrain trade jointly refusing sell prescription drugs discounted prices plaintiffs company february agreed settle federal class action behalf approximately twothirds retail pharmacies united states total paid full us district court illinois approved settlement federal class action seventh circuit court appeals dismissed appeals settlement subject review april certain plaintiffs federal class action commenced another purported class action us district court illinois company defendants settled previous federal class action complaint alleges defendants conspired implement settlement commitments following settlement discussed district court denied plaintiffs motion preliminary injunction hearing table contents company either settled dismissed motion state court retailer consumer actions settlement amounts material company federal court illinois remanded conspiracy portion cases retailers opted class action back district courts filed cases consolidated federal district court brooklyn new york federal court illinois jurisdiction robinson patman portion cases trial conspiracy claims set begin october plaintiffs antitrust actions generally seek treble damages unspecified amount injunction allegedly unlawful conduct april ftc started administrative proceeding company upshersmith inc upshersmith lederle complaint alleges anti competitive effects settlement patent lawsuits company lederle company upshersmith lawsuits settled related generic versions kdur companys longacting potassium chloride product subject andas filed lederle upshersmith june administrative law judge overseeing case issued decision patent litigation settlements complied law respects dismissed claims company appeal decision full commission filed ftc staff december full commission issued opinion reversed decision administrative law judge found violation antitrust laws ruling instead companys settlements fact violate laws ftcs decision involve monetary penalty company appealed decision federal court appeals kdur potassium chloride supplement used cardiac patients following commencement ftc administrative proceeding alleged class action suits filed behalf direct indirect purchasers kdur company upshersmith lederle federal state courts suits allege essentially facts claim violations federal state antitrust laws well state statutory andor common law causes action motion dismiss actions pending pricing matters third quarter warrick pharmaceuticals warrick companys generics subsidiary sued state texas june company subsidiary schering corporation added defendants lawsuit alleges warrick supplied state false reports wholesale prices caused state pay medicaid claims prescriptions warricks albuterol sulfate solution inhaler higherthanjustified level state seeks damages approximately warrick including treble damages penalties trial date april set outcome litigation could result imposition fines penalties injunctive remedies case goes trial assurances damages sought state exceed amount set forth states petition december pal filed class action suit federal court massachusetts company september consolidated complaint filed court result coordination multidistrict litigation panel federal court awp cases throughout country consolidated complaint alleges company warrick conspired providers defraud consumers reporting fraudulently high awps table contents prescription medications reimbursed medicare thirdparty payers complaint seeks declaratory judgment unspecified damages including treble damages included pal litigation described prior paragraph lawsuits allege company warrick reported inflated awps prescription pharmaceuticals thereby caused state federal entities thirdparty payers make excess reimbursements providers actions also allege company warrick failed report accurate prices medicaid rebate program thereby underpaid rebates states actions began october brought state attorneys general private plaintiffs nonprofit organizations employee benefit funds allege violations federal state law including fraud antitrust racketeer influenced corrupt organizations act rico claims addition warrick company defendants number lawsuits state courts actions generally brought states andor political subdivisions seek unspecified damages including treble punitive damages sec inquiries related litigation sec investigating compliance polish subsidiaries certain pharmaceutical companies us foreign corrupt practices act pursuant order dated november company voluntarily produced documents related polish subsidiary subsidiaries countries company continues cooperate secs requests company also cooperating inquiries police katowice poland asking related information september sec company announced settlement sec enforcement proceeding company richard jay kogan former chairman chief executive officer regarding meetings held investors week september communications without admitting denying allegations company agreed commit future violations regulation fd related securities laws paid civil penalty million mr kogan paid civil penalty thousand federal putative class actions filed company mr kogan regarding meetings held investors week september communications consolidated pursuant consolidation amended complaint dated march filed alleging violations sections b securities exchange act relating alleged disclosures made meetings mentioned paragraph company filed motion dismiss class actions may plaintiffs sought leave court thereafter filed second amended complaint october company moved dismiss second amended complaint september lawsuit filed new jersey superior court union county richard jay kogan companys outside directors alleging breach fiduciary duty fraud deceit negligent misrepresentation relating alleged disclosures made meetings mentioned company removed case federal court motion remand state court pending matters company subject pharmacovigilance reporting requirements many countries jurisdictions including united states european union eu eu member states requirements differ jurisdiction jurisdiction include requirements table contents reporting adverse events occur patient using particular drug order alert manufacturer drug governmental agency potential problems pharmacovigilance inspections officials british french medicines agencies conducted request european agency evaluation medicinal products emea serious deficiencies reporting processes identified company taking urgent actions rectify deficiencies quickly possible company know action emea national authorities take response findings possible actions include inspections demands improvements reporting systems criminal sanctions company andor responsible individuals changes conditions marketing authorizations companys products april company received notice false claims act complaint brought individual purporting act behalf us government approximately pharmaceutical companies us district court northern district texas complaint alleges pharmaceutical companies including company defrauded united states made sales various federal governmental agencies drugs allegedly manufactured manner comply current good manufacturing practices company defendants filed motion dismiss action july tax matters october irs auditors asserted reports company liable additional tax tax years reports allege two interest rate swaps company entered unrelated party recharacterized loans affiliated companies resulting additional tax income tax sought irs auditors relating recharacterization approximately plus interest depending upon court company chooses litigate case may required pay tax possibly interest prior litigation company estimates interest approximately company prevail litigation amounts paid prior litigation would returned company plus accrued interest company could also choose litigate case court would require payment tax interest prior litigation management believes probable matter litigated management also believes tax reserves sufficient absorb loss resulting unfavorable outcome litigation table contents independent auditors report board directors shareholders scheringplough corporation audited accompanying consolidated balance sheets scheringplough corporation subsidiaries december related consolidated statements operations shareholders equity cash flows three years period ended december audits also included financial statement schedule listed item financial statements financial statement schedule responsibility corporations management responsibility express opinion financial statements financial statement schedule based audits conducted audits accordance auditing standards generally accepted united states america standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidated financial statements present fairly material respects financial position scheringplough corporation subsidiaries december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion financial statement schedule considered relation basic consolidated financial statements taken whole presents fairly material respects information set forth therein sdeloitte touche llp parsippany new jersey february table contents scheringplough corporation subsidiaries quarterly data unaudited three months ended march june september december dollars millions except per share figures net sales cost sales gross profit selling general administrative research development income expense net special charges equity incomeloss cholesterol joint venture lossincome income taxes income tax benefitexpense net lossincome diluted lossearnings per common share basic lossearnings per common share dividends per common share common share prices high low average shares outstanding diluted eps millions average shares outstanding basic eps millions effective company presenting collaboration merck co inc merck following equity method accounting method company records share operating profits less share research development costs equity incomeloss cholesterol joint venture operating profits venture included net sales alliance revenue first three quarters reclassified equity incomeloss cholesterol joint venture also companys share ventures research development costs reported research development previous quarters reclassified equity incomeloss cholesterol joint venture second quarter company earned milestone merck reported income expense net second quarter amount also reclassified equity incomeloss cholesterol joint venture prior years affected new presentation see equity income cholesterol joint venture footnote notes consolidated financial statements additional information see special charges footnote notes consolidated financial statements additional information relating special charges table contents cost sales fourth quarter includes favorable adjustment reflect settlement arbitration relating among things royalty payments biogen full year impact material fourth quarter adjustment partially offset related accruals made previous three quarters income expense net fourth quarter includes gain sale us marketing rights suboxone subutex companys common shares listed principally traded new york stock exchange approximate number holders record common shares january table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management including chief executive officer chief financial officer evaluated companys disclosure controls procedures end period covered concluded companys disclosure controls procedures effective also concluded changes companys internal control financial reporting occurred companys recent fiscal quarter materially affected reasonably likely materially affect companys internal control financial reporting part iii item directors executive officers registrant information concerning directors nominees directors set forth captions election directors stock ownership companys proxy statement annual meeting shareholders april incorporated herein reference information required executive officers included part filing caption executive officers registrant companys board directors determined company least one audit committee financial expert serving audit committee financial expert arthur f weinbach independent defined new york stock exchange listing standards restrictive scheringplough board independence standard found scheringplough corporate governance guidelines available web site also included proxy statement required rule ab securities exchange act amended company adopted code ethics senior financial officers applies companys chief executive officer chief financial officer controller code ethics senior financial officers filed exhibit written copy code ethics senior financial officers well business conduct policy employees directors code conduct ethics provided charge writing corporate secretary scheringplough corporation galloping hill road mail stop k kenilworth new jersey also code ethics senior financial officers business conduct policy employees directors code conduct ethics available scheringplough web site httpphxcorporateirnetphoenixzhtmlcpirolgovconduct table contents item executive compensation executive compensation information set forth caption executive compensation companys proxy statement annual meeting shareholders april incorporated herein reference item security ownership certain beneficial owners management related stockholder matters information concerning security ownership certain beneficial owners management set forth caption stock ownership companys proxy statement annual meeting shareholders april incorporated herein reference equity compensation plan information following information relates plans equity securities company may issued employees directors company plans equity securities may issued nonemployees except stock incentive plan predecessor plans certain stock options may transferable family members employeeoptionee related trusts column c column number securities number securities column b remaining available future issued upon weightedaverage issuance equity exercise exercise price compensation plans outstanding options outstanding options excluding securities plan category warrants rights warrants rights reflected column equity compensation plans approved security holders stock incentive plan predecessor plans equity compensation plans approved security holders directors stock award plan na na scheringplough ireland share purchase scheme na na nonplan inducement awards approved security restricted holders shares na total table contents plan provides annual grant shares common stock nonemployee director directors may defer awards stock units pay shares common stock deferral period ends plan permits employees reside ireland enjoy tax advantages christmas bonus pay passed trustee trustee purchases shares common stock open market allocates shares employees accounts irish pounds employee may deferred year employees may sell withdraw shares allocated accounts two three years represents restricted shares awarded pursuant restricted shares agreements outside equity compensation plan adopted company mr hassan awarded restricted shares upon commencement employment april ms cox awarded restricted shares upon commencement employment may awards restricted shares vest upon third anniversary award date nonplan awards authorized compensation committee board approved stockholders company item certain relationships related transactions information concerning certain relationships related transactions set forth caption certain transactions companys proxy statement annual meeting shareholders april incorporated herein reference item principal accountant fees services information concerning principal accountant fees services set forth caption ratification designation independent auditors companys proxy statement annual meeting shareholders april incorporated herein reference table contents part iv item